BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014] [Cited by in Crossref: 1497] [Cited by in F6Publishing: 1334] [Article Influence: 88.1] [Reference Citation Analysis]
Number Citing Articles
1 Yamato I, Takayama T, Midorikawa Y, Higaki T, Nakayama H, Moriguchi M, Nakajima Y, Matsuoka S, Ogawa M, Moriyama M. Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers. Surg Today 2013;43:865-70. [DOI: 10.1007/s00595-012-0308-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
3 Kiser JJ. Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice 2009;22:405-18. [DOI: 10.1177/0897190008328695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
5 Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273:88-98. [PMID: 24893048 DOI: 10.1148/radiol.14132] [Reference Citation Analysis]
6 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
7 Zhu YF, Tan YF, Xu X, Zheng JL, Zhang BH, Tang HR, Yang JY. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. Medicine (Baltimore) 2019;98:e18319. [PMID: 31852119 DOI: 10.1097/MD.0000000000018319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, Nakao K. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci. 2011;56:3086-3100. [PMID: 21706206 DOI: 10.1007/s10620-011-1796-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
9 Gordon SC. Occult viral hepatitis and noncirrhotic hepatocellular carcinoma. Am J Gastroenterol. 2005;100:1754-1757. [PMID: 16144125 DOI: 10.1111/j.1572-0241.2005.50483.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
10 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 6.9] [Reference Citation Analysis]
11 Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412. [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009] [Cited by in Crossref: 148] [Cited by in F6Publishing: 139] [Article Influence: 18.5] [Reference Citation Analysis]
12 Cheinquer N, Cheinquer H, Wolff FH, Coelho-borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. The Brazilian Journal of Infectious Diseases 2010;14:457-61. [DOI: 10.1016/s1413-8670(10)70093-3] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
13 Ruggieri A, Franco M, Gatto I, Kumar A, Rapicetta M. Modulation of RANTES expression by HCV core protein in liver derived cell lines. BMC Gastroenterol 2007;7:21. [PMID: 17565659 DOI: 10.1186/1471-230X-7-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Chang M, Chen T, Chang M, Yeh C. Cell cycle perturbation in the hepatocytes of HCV core transgenic mice following common bile duct ligation is associated with enhanced p21 expression. J Med Virol 2009;81:467-72. [DOI: 10.1002/jmv.21403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology. 2013;266:480-490. [PMID: 23362095 DOI: 10.1148/radiol.12112677] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
16 Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124. [PMID: 17615358 DOI: 10.1126/science.1140485] [Cited by in Crossref: 1224] [Cited by in F6Publishing: 1126] [Article Influence: 87.4] [Reference Citation Analysis]
17 Del Campo JA, García-Valdecasas M, Gil-Gómez A, Rojas Á, Gallego P, Ampuero J, Gallego-Durán R, Pastor H, Grande L, Padillo FJ, Muntané J, Romero-Gómez M. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS One 2018;13:e0191805. [PMID: 29385181 DOI: 10.1371/journal.pone.0191805] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
18 Rizzetto M, Ciancio A. Chronic HBV-related liver disease. Mol Aspects Med. 2008;29:72-84. [PMID: 18067957 DOI: 10.1016/j.mam.2007.09.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
19 Tsunematsu H, Tatsumi T, Kohga K, Yamamoto M, Aketa H, Miyagi T, Hosui A, Hiramatsu N, Kanto T, Hayashi N. Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. Int J Cancer. 2012;130:356-364. [PMID: 21351090 DOI: 10.1002/ijc.26003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
20 Lv X, Fang C, Yin R, Qiao B, Shang R, Wang J, Song W, He Y, Chen Y. Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget 2017;8:105340-55. [PMID: 29285255 DOI: 10.18632/oncotarget.22186] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
21 Caviglia JM, Schwabe RF. Mouse models of liver cancer. Methods Mol Biol 2015;1267:165-83. [PMID: 25636469 DOI: 10.1007/978-1-4939-2297-0_8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
22 Guro H, Cho JY, Han HS, Yoon YS, Choi Y, Periyasamy M. Current status of laparoscopic liver resection for hepatocellular carcinoma. Clin Mol Hepatol. 2016;22:212-218. [PMID: 27304550 DOI: 10.3350/cmh.2016.0026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
23 Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai Y, Nakamura M, Takatori H, Sunagozaka H. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Genomics. 2013;101:238-248. [PMID: 23485556 DOI: 10.1016/j.ygeno.2013.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
24 Lee DW, Jang MJ, Lee KH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer 2016;115:1201-5. [PMID: 27736843 DOI: 10.1038/bjc.2016.322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for the study of HCV infection and virus-host interactions. J Hepatol. 2008;49:134-142. [PMID: 18457898 DOI: 10.1016/j.jhep.2008.03.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
26 Lin X, Peng Z, Fu X, Liu C, Xu Y, Ji W, Fan J, Chen L, Fang L, Huang Y, Su C. Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma. Oncotarget 2016;7:79761-73. [PMID: 27806329 DOI: 10.18632/oncotarget.12962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Xu X, Liu X, Liang M, Luo B. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology 2018;287:461-72. [DOI: 10.1148/radiol.2017162756] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 22.0] [Reference Citation Analysis]
28 Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature. J Family Med Prim Care 2020;9:531-8. [PMID: 32318377 DOI: 10.4103/jfmpc.jfmpc_943_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Karageorgos SA, Stratakou S, Koulentaki M, Voumvouraki A, Mantaka A, Samonakis D, Notas G, Kouroumalis EA. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol 2017;30:357-63. [PMID: 28469367 DOI: 10.20524/aog.2017.0135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
30 Okamoto E, Sato S, Sanchez-Siles AA, Ishine J, Miyake T, Amano Y, Kinoshita Y. Evaluation of virtual CT sonography for enhanced detection of small hepatic nodules: a prospective pilot study. AJR Am J Roentgenol 2010;194:1272-8. [PMID: 20410414 DOI: 10.2214/AJR.08.2294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
31 Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon. 2013;13:e8351. [PMID: 24066001 DOI: 10.5812/hepatmon.8351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
32 Goessling W. Deciphering Hepatocellular Carcinoma: From Bench to Bedside and Back. Gastroenterology 2009;137:786-8. [DOI: 10.1053/j.gastro.2009.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
34 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
35 Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453-458. [PMID: 17725599 DOI: 10.1111/j.1440-1746.2007.05120.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
36 Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008;15:246-9. [DOI: 10.1111/j.1365-2893.2007.00935.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
37 Chen Z, Zhu J, Huang C, Lian F, Wu G, Zhao Y. The association between three cyclooxygenase-2 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. PLoS One. 2015;10:e0118251. [PMID: 25730260 DOI: 10.1371/journal.pone.0118251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Silva AC, Evans JM, McCullough AE, Jatoi MA, Vargas HE, Hara AK. MR imaging of hypervascular liver masses: a review of current techniques. Radiographics. 2009;29:385-402. [PMID: 19325055 DOI: 10.1148/rg.292085123] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
39 Winnock M, Neau D, Castera L, Viot J, Lacoste D, Pellegrin JL, Dupon M, Jutand MA, Colombani F, Dabis F, Dabis F. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroentérologie Clinique et Biologique 2006;30:189-95. [DOI: 10.1016/s0399-8320(06)73153-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007;46:1350-1356. [PMID: 17680653 DOI: 10.1002/hep.21826] [Cited by in Crossref: 125] [Cited by in F6Publishing: 125] [Article Influence: 8.9] [Reference Citation Analysis]
41 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Reference Citation Analysis]
42 Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras (1992) 2013;59:514-24. [PMID: 24041910 DOI: 10.1016/j.ramb.2013.03.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
43 Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015;44:807-824. [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
44 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
45 Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int 2019;39:1217-25. [PMID: 30912255 DOI: 10.1111/liv.14104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018;17:377-84. [PMID: 30923667 DOI: 10.1007/s11901-018-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. J Viral Hepat 2017;24:1089-97. [PMID: 28581644 DOI: 10.1111/jvh.12736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ertel AE, Shah SA. Surgical Approaches to Hepatocellular Carcinoma. Semin Roentgenol 2016;51:88-94. [PMID: 27105963 DOI: 10.1053/j.ro.2016.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev Syst Biol Med. 2020;e1499. [PMID: 32713091 DOI: 10.1002/wsbm.1499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Bu Y, Jia QA, Ren ZG, Xue TC, Zhang QB, Zhang KZ, Zhang QB, You Y, Tian H, Qin LX, Tang ZY. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget 2015;6:40068-80. [PMID: 26517671 DOI: 10.18632/oncotarget.5313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
51 Moriwaki H, Shiraki M, Fukushima H, Shimizu M, Iwasa J, Naiki T, Nagaki M. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis. Hepatol Res. 2008;38:S102-S106. [PMID: 19125940 DOI: 10.1111/j.1872-034x.2008.00434.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
52 Marquardt JU, Quasdorff M, Varnholt H, Curth HM, Mesghenna S, Protzer U, Goeser T, Nierhoff D. Neighbor of Punc E11, a novel oncofetal marker for hepatocellular carcinoma. Int J Cancer. 2011;128:2353-2363. [PMID: 20658536 DOI: 10.1002/ijc.25567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
53 Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013;19:5622-32. [PMID: 24039354 DOI: 10.3748/wjg.v19.i34.5622] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
54 Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007;121:1624-6. [PMID: 17557292 DOI: 10.1002/ijc.22860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
55 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 227] [Article Influence: 21.1] [Reference Citation Analysis]
56 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
57 Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noé G, Farinotti R, Bonhomme-Faivre L. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemother Pharmacol 2017;79:759-66. [PMID: 28289864 DOI: 10.1007/s00280-017-3268-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
58 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
59 Lin CL, Kao JH. Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. Gastroenterol Clin North Am. 2020;49:201-214. [PMID: 32389359 DOI: 10.1016/j.gtc.2020.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
60 Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008;173:856-864. [PMID: 18688024 DOI: 10.2353/ajpath.2008.080096] [Cited by in Crossref: 193] [Cited by in F6Publishing: 179] [Article Influence: 14.8] [Reference Citation Analysis]
61 Noreikaite J, Albasha D, Chidambaram V, Arora A, Katti A. Indeterminate liver lesions on gadoxetic acid-enhanced magnetic resonance imaging of the liver: Case-based radiologic-pathologic review. WJH 2021;13:1079-97. [DOI: 10.4254/wjh.v13.i9.1079] [Reference Citation Analysis]
62 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Rustgi V, Carriero D, Bachtold M, Zeldin G. Update on Chronic Hepatitis B. The Journal for Nurse Practitioners 2010;6:631-9. [DOI: 10.1016/j.nurpra.2010.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014;20:15007-17. [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
65 White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012;55:759-768. [PMID: 21858849 DOI: 10.1002/hep.24618] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
66 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 369] [Article Influence: 37.8] [Reference Citation Analysis]
67 Ansardamavandi A, Tafazzoli-Shadpour M, Omidvar R, Nili F. An AFM-Based Nanomechanical Study of Ovarian Tissues with Pathological Conditions. Int J Nanomedicine 2020;15:4333-50. [PMID: 32606681 DOI: 10.2147/IJN.S254342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
68 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 184] [Article Influence: 31.5] [Reference Citation Analysis]
69 Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M, Shibata H, Sato S, Miyaaki H, Nakao K. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Intern Med 2020;59:901-7. [PMID: 32238660 DOI: 10.2169/internalmedicine.3382-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
71 Molina-Aguilar C, Guerrero-Carrillo MJ, Espinosa-Aguirre JJ, Olguin-Reyes S, Castro-Belio T, Vázquez-Martínez O, Rivera-Zavala JB, Díaz-Muñoz M. Time-caloric restriction inhibits the neoplastic transformation of cirrhotic liver in rats treated with diethylnitrosamine. Carcinogenesis 2017;38:847-58. [PMID: 28535183 DOI: 10.1093/carcin/bgx052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
72 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
73 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018;10:898-906. [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Ziol M, Nault J, Aout M, Barget N, Tepper M, Martin A, Trinchet J, Ganne–carrié N, Vicaut E, Beaugrand M, N'kontchou G. Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis. Gastroenterology 2010;139:335-343.e2. [DOI: 10.1053/j.gastro.2010.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
75 Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther 2011;34:83-91. [PMID: 21535445 DOI: 10.1111/j.1365-2036.2011.04673.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
76 Wei X, Liu H, Li X, Liu X. Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4. Ann Hepatol 2019;18:869-78. [PMID: 31477445 DOI: 10.1016/j.aohep.2019.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
77 Zhang X, Zhang W, Ye L. Pathogenesis of hepatitis B virus infection. Future Virology 2006;1:637-47. [DOI: 10.2217/17460794.1.5.637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Xue C, Zhong Z, Ye S, Wang Y, Ye Q. Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma. Oncol Lett 2018;16:3401-7. [PMID: 30127941 DOI: 10.3892/ol.2018.9013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Mair RD, Valenzuela A, Ha NB, Ayoub WS, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012;10:1412-7. [PMID: 22902757 DOI: 10.1016/j.cgh.2012.08.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
80 Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of Virus Eradication 2019;5:116-21. [DOI: 10.1016/s2055-6640(20)30053-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Kaufmann S, Schulze M, Spira D, Horger M. Modern multimodality diagnosis of portal vein infiltration in hepatocellular carcinoma and expected changes during current therapies. Acta Radiol 2015;56:1283-92. [DOI: 10.1177/0284185114556305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology. 2010;51:1264-1273. [PMID: 20099300 DOI: 10.1002/hep.23456] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 8.1] [Reference Citation Analysis]
83 Liu J, Zhang G, Lv Y, Zhang X, Ying C, Yang S, Kong X, Yu Y. SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3β/β-catenin signaling in HCC cells. Tumour Biol 2017;39:101042831770040. [DOI: 10.1177/1010428317700408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
84 Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015;121:3631-8. [PMID: 26177866 DOI: 10.1002/cncr.29537] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 18.2] [Reference Citation Analysis]
85 Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H. Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway. PLoS One 2020;15:e0230263. [PMID: 32163489 DOI: 10.1371/journal.pone.0230263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
86 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 13.3] [Reference Citation Analysis]
87 Gonçalves PL, Zago-Gomes Mda P, Gonçalves CS, Pereira FE. Hepatitis virus and hepatocellular carcinoma in Brazil: a report from the State of Espírito Santo. Rev Soc Bras Med Trop. 2014;47:559-563. [PMID: 25467255 DOI: 10.1590/0037-8682-0145-2014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018;41:819-27. [PMID: 29423829 DOI: 10.1007/s10545-018-0142-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
89 Irshad M, Gupta P, Irshad K. Immunopathogenesis of Liver Injury During Hepatitis C Virus Infection. Viral Immunol 2019;32:112-20. [PMID: 30817236 DOI: 10.1089/vim.2018.0124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
90 Guo JC, Yang YJ, Zheng JF, Zhang JQ, Guo M, Yang X, Jiang XL, Xiang L, Li Y, Ping H, Zhuo L. Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med 2019;51:1-20. [PMID: 31757938 DOI: 10.1038/s12276-019-0328-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
91 Børresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, Panum I, Simonetti J, Jones C, Krarup H, Koch A. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010;17:162-170. [PMID: 19780937 DOI: 10.1111/j.1365-2893.2009.01159.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
92 Shan S, Chen W, Jia JD. Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development. Front Genet 2019;10:305. [PMID: 31001331 DOI: 10.3389/fgene.2019.00305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
93 Lee SS, Jeong S, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC, Kee M, Kang C. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea: Outcomes of HCV-related cirrhosis. J Gastroenterol Hepatol 2015;30:1281-7. [DOI: 10.1111/jgh.12950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
94 Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191-197. [PMID: 26213370 DOI: 10.1016/j.canlet.2015.07.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
95 Cassim S, Raymond VA, Lacoste B, Lapierre P, Bilodeau M. Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma. Oncotarget 2018;9:26868-83. [PMID: 29928490 DOI: 10.18632/oncotarget.25525] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
96 Méndez-sánchez; N, Vásquez-fernández; F, Zamora-valdés; D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology 2008;7:46-51. [DOI: 10.1016/s1665-2681(19)31886-1] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
97 Dokkaew A, Punvittayagul C, Insuan O, Limtrakul Dejkriengkraikul P, Wongpoomchai R. Protective Effects of Defatted Sticky Rice Bran Extracts on the Early Stages of Hepatocarcinogenesis in Rats. Molecules 2019;24:E2142. [PMID: 31174320 DOI: 10.3390/molecules24112142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
98 Elnekave E, Erinjeri JP, Brown KT, Thornton RH, Petre EN, Maybody M, Maluccio MA, Hsu M, Sofocleous CT, Getrajdman GI. Long-term outcomes comparing surgery to embolization-ablation for treatment of solitary HCC& lt; 7 cm. Ann Surg Oncol. 2013;20:2881-2886. [PMID: 23563960 DOI: 10.1245/s10434-013-2961-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
99 Chin'ombe N, Chavhunduka E, Matarira HT. Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe. Infect Agent Cancer 2009;4:15. [PMID: 19814789 DOI: 10.1186/1750-9378-4-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
100 Chu C, Deng J, Man Y, Qu Y. Green Tea Extracts Epigallocatechin-3-gallate for Different Treatments. Biomed Res Int. 2017;2017:5615647. [PMID: 28884125 DOI: 10.1155/2017/5615647] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 21.8] [Reference Citation Analysis]
101 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010;2:114-26. [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
102 Lee M, Ko H, Yun M. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma. Yonsei Med J 2018;59:1143-9. [PMID: 30450847 DOI: 10.3349/ymj.2018.59.10.1143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
103 Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, Tsugane S; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2008;38:816-38. [PMID: 18945722 DOI: 10.1093/jjco/hyn108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
104 Rauwolf K, Herbrüggen H, Zöllner S, Thorer H, Makarova O, Kaiser T, Pettke A, Rossig C, Burkhardt B, Groll AH. Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation. J Viral Hepat 2019;26:454-8. [PMID: 30516856 DOI: 10.1111/jvh.13046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
106 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
107 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013;19:3207-16. [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
108 Sofue K, Burke LM, Nilmini V, Alagiyawanna M, Muir AJ, Choudhury KR, Jaffe TA, Semelka RC, Bashir MR. Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5: LI-RADS Category 4 Observations in MRI. J Magn Reson Imaging 2017;46:783-92. [DOI: 10.1002/jmri.25627] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
109 Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. Korean J Intern Med 2021;36:544-56. [PMID: 30879288 DOI: 10.3904/kjim.2018.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
110 Wang Z, Teng D, Li Y, Hu Z, Liu L, Zheng H. A six-gene-based prognostic signature for hepatocellular carcinoma overall survival prediction. Life Sci 2018;203:83-91. [PMID: 29678742 DOI: 10.1016/j.lfs.2018.04.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
111 Liu X, Tang R. Localized delivery of chemokine for in vitro manipulation of hepatocellular carcinoma cell behaviors during the epithelial–mesenchymal transition. J Biomater Appl 2017;32:945-56. [DOI: 10.1177/0885328217745774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Gonçalves PL, Zago-Gomes Mda P, Marques CC, Mendonça AT, Gonçalves CS, Pereira FE. Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espírito Santo. Clinics (Sao Paulo) 2013;68:291-5. [PMID: 23644846 DOI: 10.6061/clinics/2013(03)oa02] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
113 Hou SC, Xiao MB, Ni RZ, Ni WK, Jiang F, Li XY, Lu CH, Chen BY. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett 2013;6:1152-8. [PMID: 24137480 DOI: 10.3892/ol.2013.1522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
114 Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 2011;15:1433-1439. [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
115 Vallet-Pichard A, Mallet V, Costentin CE, Pol S. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther. 2009;7:527-535. [PMID: 19485793 DOI: 10.1586/eri.09.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
116 Konreddy AK, Rani GU, Lee K, Choi Y. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics. Curr Med Chem 2019;26:5363-88. [PMID: 29984648 DOI: 10.2174/0929867325666180706101404] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
117 Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014;109:325-34. [PMID: 24445574 DOI: 10.1038/ajg.2013.476] [Cited by in Crossref: 184] [Cited by in F6Publishing: 163] [Article Influence: 26.3] [Reference Citation Analysis]
118 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019;25:2416-29. [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
119 Lee CH, Kim IH, Moon JC, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Yang JD, Yu HC. 3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy. World J Gastroenterol 2017;23:297-305. [PMID: 28127203 DOI: 10.3748/wjg.v23.i2.297] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
121 Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, García-Deltoro M, Rivero-Juárez A, Téllez F, Delgado-Fernández M, Ríos-Villegas MJ, García MA, Vera-Méndez FJ, Ojeda-Burgos G, López-Ruz MA, Metola L, Omar M, Alemán-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macías J, Pineda JA; GEHEP-002 Study Group. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 2018;32:1423-30. [PMID: 29596108 DOI: 10.1097/QAD.0000000000001809] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 7.5] [Reference Citation Analysis]
122 Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol 2015;7:2590-6. [PMID: 26557951 DOI: 10.4254/wjh.v7.i25.2590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
123 Majeed A, Roberts SK, Kemp W. RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology 2019;156:1217. [DOI: 10.1053/j.gastro.2018.09.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Cao N, Mu L, Yang W, Liu L, Liang L, Zhang H. MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/β-catenin signaling. Biomed Pharmacother 2018;106:483-90. [PMID: 29990836 DOI: 10.1016/j.biopha.2018.06.135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
125 Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7:267. [PMID: 31627733 DOI: 10.1186/s40425-019-0749-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
126 Chang JM, Huang KL, Yuan TT, Lai YK, Hung LM. The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice. Evid Based Complement Alternat Med 2010;7:189-95. [PMID: 18955304 DOI: 10.1093/ecam/nem180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
127 Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42:179-190. [PMID: 27448609 DOI: 10.1007/s00261-016-0841-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 22.7] [Reference Citation Analysis]
128 Wang J, Zuo Y, Man YG, Avital I, Stojadinovic A, Liu M, Yang X, Varghese RS, Tadesse MG, Ressom HW. Pathway and network approaches for identification of cancer signature markers from omics data. J Cancer 2015;6:54-65. [PMID: 25553089 DOI: 10.7150/jca.10631] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
129 Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, Lu SN. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. J Gastroenterol 2010;45:636-45. [PMID: 20054698 DOI: 10.1007/s00535-009-0189-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
130 Tanase AM, Dumitrascu T, Dima S, Grigorie R, Marchio A, Pineau P, Popescu I. Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014;13:162-72. [PMID: 24686543 DOI: 10.1016/s1499-3872(14)60026-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
131 Nicolini A, Crespi S, Martinetti L. Drug delivery embolization systems: a physician's perspective. Expert Opin Drug Deliv 2011;8:1071-84. [PMID: 21692688 DOI: 10.1517/17425247.2011.590472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
132 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
133 Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010;27:512-22. [PMID: 20652658 DOI: 10.1007/s12325-010-0047-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
134 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
136 Wang WH, Jiang CL, Yan W, Zhang YH, Yang JT, Zhang C, Yan B, Zhang W, Han W, Wang JZ, Zhang YQ. FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol 2010;16:5502-9. [PMID: 21086571 DOI: 10.3748/wjg.v16.i43.5502] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
137 Calvaruso V, Craxì A. Hepatocellular carcinoma and direct-acting antivirals: A never ending story? Liver Int 2017;37:812-4. [PMID: 28544693 DOI: 10.1111/liv.13421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Sakisaka M, Haruta M, Komohara Y, Umemoto S, Matsumura K, Ikeda T, Takeya M, Inomata Y, Nishimura Y, Senju S. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci 2017;24:109-19. [PMID: 28008721 DOI: 10.1002/jhbp.422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
139 Amin J, Dore GJ, O’Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol. 2006;45:197-203. [PMID: 16684579 DOI: 10.1016/j.jhep.2006.02.014] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 6.7] [Reference Citation Analysis]
140 Zhu Y, Cui PJ, Yao J, Zhang ZY, Yang J. Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterol Res Pract 2018;2018:6414759. [PMID: 29805444 DOI: 10.1155/2018/6414759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Gan WJ, Wang JR, Zhu XL, He XS, Guo PD, Zhang S, Li XM, Li JM, Wu H. RARγ-induced E-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis. J Exp Clin Cancer Res 2016;35:164. [PMID: 27756432 DOI: 10.1186/s13046-016-0441-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
142 Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MAD, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology 2012;56:1089-96. [DOI: 10.1016/j.jhep.2011.11.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
143 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014;20:6262-78. [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 77] [Article Influence: 13.8] [Reference Citation Analysis]
144 Thuluvath PJ. EUS-guided FNA could be another important tool for the early diagnosis of hepatocellular carcinoma. Gastrointestinal Endoscopy 2007;66:274-6. [DOI: 10.1016/j.gie.2006.12.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
145 Barr RG. Ultrasound of Diffuse Liver Disease Including Elastography. Radiol Clin North Am 2019;57:549-62. [PMID: 30928077 DOI: 10.1016/j.rcl.2019.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
146 Wang C, Yang M, Zhao J, Li X, Xiao X, Zhang Y, Jin X, Liao M. Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. J Cell Physiol 2019;234:10899-906. [DOI: 10.1002/jcp.27905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
147 Jatapai A, Nelson KE, Chuenchitra T, Kana K, Eiumtrakul S, Sunantarod E, Rangsin R. Prevalence and risk factors for hepatitis C virus infection among young Thai men. Am J Trop Med Hyg 2010;83:433-9. [PMID: 20682895 DOI: 10.4269/ajtmh.2010.09-0749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
148 Morling JR, Fallowfield JA, Guha IN, Williamson RM, Ali M, Glancy S, Strachan MW, Price JF. Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study. QJM 2016;109:249-56. [PMID: 26454513 DOI: 10.1093/qjmed/hcv191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
149 Naugler WE, Schwartz JM. Hepatocellular carcinoma. Dis Mon 2008;54:432-44. [PMID: 18570913 DOI: 10.1016/j.disamonth.2008.03.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
150 Wei T, Chen W, Wen L, Zhang J, Zhang Q, Yang J, Liu H, Chen BW, Zhou Y, Feng X, Yang Q, Bai X, Liang T. G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. Cancer Letters 2016;382:195-202. [DOI: 10.1016/j.canlet.2016.08.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
151 ELBassuoni MA, Abd El Fatah G, Zaghla H. IL17A gene polymorphism, serum IL17 and total IgE in Egyptian population with chronic HCV and hepatocellular carcinoma. Immunol Lett 2015;168:240-5. [PMID: 26367076 DOI: 10.1016/j.imlet.2015.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
152 Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 2020;30:2302-11. [DOI: 10.1007/s00330-019-06546-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
153 Seo N, Chung YE, Park YN, Kim E, Hwang J, Kim MJ. Liver fibrosis: stretched exponential model outperforms mono-exponential and bi-exponential models of diffusion-weighted MRI. Eur Radiol. 2018;28:2812-2822. [PMID: 29404771 DOI: 10.1007/s00330-017-5292-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
154 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
155 Ertel AE, Chang AL, Kim Y, Shah SA. Management of gastrointestinal bleeding in patients with cirrhosis. Curr Probl Surg 2016;53:366-95. [PMID: 27585818 DOI: 10.1067/j.cpsurg.2016.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
156 Chang TT, Thakar D, Weaver VM. Force-dependent breaching of the basement membrane. Matrix Biol 2017;57-58:178-89. [PMID: 28025167 DOI: 10.1016/j.matbio.2016.12.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
157 Ma X, Yu C, Wang P, Xu W, Wan X, Lai CSE, Liu J, Koroleva-Maharajh A, Chen S. Rapid 3D bioprinting of decellularized extracellular matrix with regionally varied mechanical properties and biomimetic microarchitecture. Biomaterials 2018;185:310-21. [PMID: 30265900 DOI: 10.1016/j.biomaterials.2018.09.026] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 26.7] [Reference Citation Analysis]
158 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 302] [Article Influence: 31.0] [Reference Citation Analysis]
159 Su CL, Chen FN, Won SJ. Involvement of apoptosis and autophagy in reducing mouse hepatoma ML-1 cell growth in inbred BALB/c mice by bacterial fermented soybean products. Food Chem Toxicol. 2011;49:17-24. [PMID: 20732379 DOI: 10.1016/j.fct.2010.08.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
160 Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1-17. [PMID: 25444466 DOI: 10.1016/j.soc.2014.09.001] [Cited by in Crossref: 168] [Cited by in F6Publishing: 158] [Article Influence: 24.0] [Reference Citation Analysis]
161 Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc Pharmacol 2014; 66: 14.30.1-14. 3010;. [PMID: 25181010 DOI: 10.1002/0471141755.ph1430s66] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
162 Wang Q, Zhang P, Li Z, Feng X, Lv C, Zhang H, Xiao H, Ding J, Chen X. Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. Theranostics 2019;9:1426-52. [PMID: 30867842 DOI: 10.7150/thno.31683] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
163 Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg. 2012;397:673-680. [PMID: 21479622 DOI: 10.1007/s00423-011-0783-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
164 Sahu SK, Taneja S, Kalra N, Dhiman RK, Chawla YK, Duseja A, Singh V. Rupture of Hepatocellular Carcinoma: a Tale of 20 Cases from a Tertiary Care Center in Northern India. J Gastrointest Cancer 2019;50:596-600. [PMID: 29399732 DOI: 10.1007/s12029-018-0063-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
165 Li HG, Liu FF, Zhu HQ, Zhou X, Lu J, Chang H, Hu JH. Significant Association Between Adiponutrin and Hepatocellular Carcinoma Risk. Medicine (Baltimore) 2015;94:e2019. [PMID: 26632699 DOI: 10.1097/MD.0000000000002019] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
166 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
167 Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Mol Cancer Ther 2016;15:731-42. [PMID: 26939703 DOI: 10.1158/1535-7163.MCT-15-0706] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
168 Wu S, Zheng Q, Xing X, Dong Y, Wang Y, You Y, Chen R, Hu C, Chen J, Gao D, Zhao Y, Wang Z, Xue T, Ren Z, Cui J. Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. J Exp Clin Cancer Res 2018;37:99. [PMID: 29728125 DOI: 10.1186/s13046-018-0761-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
169 Vaz J, Strömberg U, Eriksson B, Buchebner D, Midlöv P. Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. BMC Public Health 2020;20:1820. [PMID: 33256682 DOI: 10.1186/s12889-020-09783-2] [Reference Citation Analysis]
170 Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, Yuen MF. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat 2019;26:818-27. [PMID: 30895682 DOI: 10.1111/jvh.13095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
171 Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009;13:1411-27. [PMID: 19874261 DOI: 10.1517/14728220903307509] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 10.7] [Reference Citation Analysis]
172 Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol 2015;15:98. [PMID: 26239358 DOI: 10.1186/s12876-015-0320-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
173 Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013;8:e55761. [PMID: 23437062 DOI: 10.1371/journal.pone.0055761] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 9.4] [Reference Citation Analysis]
174 Yamamoto M, Tatsumi T, Miyagi T, Tsunematsu H, Aketa H, Hosui A, Kanto T, Hiramatsu N, Hayashi N, Takehara T. α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165:211-219. [PMID: 21592114 DOI: 10.1111/j.1365-2249.2011.04421.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
175 Chang KC, Lu SN, Chen PF, Hung CH, Kee KM, Yen YH, Wang JH. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study. Kaohsiung J Med Sci 2011;27:85-90. [PMID: 21421195 DOI: 10.1016/j.kjms.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
176 Lin C, Kao J. The clinical implications of hepatitis B virus genotype: Recent advances: HBV genotype and clinical outcomes. Journal of Gastroenterology and Hepatology 2011;26:123-30. [DOI: 10.1111/j.1440-1746.2010.06541.x] [Cited by in Crossref: 222] [Cited by in F6Publishing: 210] [Article Influence: 22.2] [Reference Citation Analysis]
177 Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology 2010;56:683-93. [PMID: 20546333 DOI: 10.1111/j.1365-2559.2010.03554.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
178 Cholankeril G, Yoo ER, Perumpail RB, Liu A, Sandhu JS, Nair S, Hu M, Ahmed A. Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease. Diseases 2017;5:E20. [PMID: 28954412 DOI: 10.3390/diseases5040020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
179 Sato M, Hikita H, Hagiwara S, Sato M, Soroida Y, Suzuki A, Gotoh H, Iwai T, Kojima S, Matsuura T. Potential associations between perihepatic lymph node enlargement and liver fibrosis, hepatocellular injury or hepatocarcinogenesis in chronic hepatitis B virus infection. Hepatol Res. 2015;45:397-404. [PMID: 24849617 DOI: 10.1111/hepr.12361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
180 Kim MS, Ong M, Qu X. Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol. 2016;22:8-23. [PMID: 26755857 DOI: 10.3748/wjg.v22.i1.8] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
181 Shimizu K, Soroida Y, Sato M, Hikita H, Kobayashi T, Endo M, Sato M, Gotoh H, Iwai T, Tateishi R, Koike K, Yatomi Y, Ikeda H. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Sci Rep 2018;8:7845. [PMID: 29777191 DOI: 10.1038/s41598-018-26293-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
182 Marrero JA. Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers. Journal of Hepatology 2009;50:659-61. [DOI: 10.1016/j.jhep.2009.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
183 Tavakoli-tabasi S, Ninan S. Clinical Significance of Perihepatic Lymphadenopathy in Patients with Chronic Hepatitis C Infection. Dig Dis Sci 2011;56:2137-44. [DOI: 10.1007/s10620-010-1555-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
184 Chung SI, Moon H, Kim DY, Cho KJ, Ju HL, Kim DY, Ahn SH, Han KH, Ro SW. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterol 2016;16:13. [PMID: 26821924 DOI: 10.1186/s12876-016-0423-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
185 Wu MS, Wang CH, Tseng FC, Yang HJ, Lo YC, Kuo YP, Tsai DJ, Tsai WT, Yu GY. Interleukin-17F expression is elevated in hepatitis C patients with fibrosis and hepatocellular carcinoma. Infect Agent Cancer 2017;12:42. [PMID: 28770001 DOI: 10.1186/s13027-017-0152-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
186 Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu K. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2020;12:8016-29. [PMID: 31997633 DOI: 10.1021/acsami.9b22802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
187 Sikora D, Greco-Stewart VS, Miron P, Pelchat M. The hepatitis delta virus RNA genome interacts with eEF1A1, p54(nrb), hnRNP-L, GAPDH and ASF/SF2. Virology. 2009;390:71-78. [PMID: 19464723 DOI: 10.1016/j.virol.2009.04.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
188 Mariano A, Caserta C, Pendino G, Vacalebre C, Surace P, Fiorillo M, Polito I, Surace M, Alicante S, Amante A, Foti G, Marra M, Gutamo G, Amato F, Messineo A, Mele A. Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic area. Digestive and Liver Disease 2009;41:509-15. [DOI: 10.1016/j.dld.2008.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
189 Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol 2021;37:200-7. [PMID: 33654016 DOI: 10.1097/MOG.0000000000000716] [Reference Citation Analysis]
190 Chung SI, Moon H, Ju HL, Cho KJ, Kim DY, Han KH, Eun JW, Nam SW, Ribback S, Dombrowski F, Calvisi DF, Ro SW. Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. J Hepatol 2016;64:618-27. [PMID: 26471504 DOI: 10.1016/j.jhep.2015.10.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
191 Chuma M, Hige S, Nakanishi M, Ogawa K, Natsuizaka M, Yamamoto Y, Asaka M. 8-Hydroxy-2’-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2008;23:1431-1436. [PMID: 18854000 DOI: 10.1111/j.1440-1746.2008.05502.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
192 Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Villalobos M, Omar M, Rincón P, Rivero A, Pérez-Pérez M, Raffo M, López-Montesinos I, Palacios R, Gómez-Vidal MA, Macías J, Pineda JA; Members of the HEPAVIR-Cirrhosis Study Group. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother 2018;73:2435-43. [PMID: 29982683 DOI: 10.1093/jac/dky234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
193 Frohlich J, Kovacovicova K, Mazza T, Emma MR, Cabibi D, Foti M, Sobolewski C, Oben JA, Peyrou M, Villarroya F, Soresi M, Rezzani R, Cervello M, Bonomini F, Alisi A, Vinciguerra M. GDF11 induces mild hepatic fibrosis independent of metabolic health. Aging (Albany NY) 2020;12:20024-46. [PMID: 33126224 DOI: 10.18632/aging.104182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
194 Motz VL, White R, Lee R, Vu T, Shin B, McGillen KL. Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. Abdom Radiol (NY) 2021;46:4170-7. [PMID: 33956204 DOI: 10.1007/s00261-021-03104-w] [Reference Citation Analysis]
195 Kamarajah SK, Bundred JR, Littler P, Reeves H, Manas DM, White SA. Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. HPB (Oxford) 2021;23:495-505. [PMID: 33309569 DOI: 10.1016/j.hpb.2020.10.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Gan Y, Liang Q, Song X. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2014;35:3953-3960. [PMID: 24395655 DOI: 10.1007/s13277-013-1563-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
197 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013;19:1359-71. [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
198 Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166-1175. [PMID: 18382459 DOI: 10.1038/sj.bjc.6604301] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
199 Kim NH, Kim HJ, Cho YK, Hong HP, Kim BI. Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization. J Korean Med Sci 2019;34:e208. [PMID: 31373186 DOI: 10.3346/jkms.2019.34.e208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol. 2013;19:8808-8821. [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
201 Gao L, Zhang Z, Zhang P, Yu M, Yang T. Role of canonical Hedgehog signaling pathway in liver. Int J Biol Sci. 2018;14:1636-1644. [PMID: 30416378 DOI: 10.7150/ijbs.28089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
202 Dong Y, Zheng Q, Wang Z, Lin X, You Y, Wu S, Wang Y, Hu C, Xie X, Chen J, Gao D, Zhao Y, Wu W, Liu Y, Ren Z, Chen R, Cui J. Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis. J Hematol Oncol 2019;12:112. [PMID: 31703598 DOI: 10.1186/s13045-019-0795-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
203 Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, Gorsi U. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol 2019;9:245-56. [PMID: 31024207 DOI: 10.1016/j.jceh.2018.04.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
204 Kraus MR, Schäfer A, Teuber G, Porst H, Sprinzl K, Wollschläger S, Keicher C, Scheurlen M. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology. 2013;58:497-504. [PMID: 23300053 DOI: 10.1002/hep.26229] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
205 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
206 Ding B, Lou W, Liu J, Li R, Chen J, Fan W. In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. Cancer Cell Int. 2019;19:186. [PMID: 31346321 DOI: 10.1186/s12935-019-0901-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
207 Sakai H, Miwa T, Ikoma Y, Hanai T, Nakamura N, Imai K, Kitagawa J, Shirakami Y, Kanemura N, Suetsugu A, Takai K, Shiraki M, Shimizu M. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review. Mol Clin Oncol 2020;13:1. [PMID: 32754315 DOI: 10.3892/mco.2020.2071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Chen Q, Tang H, Zha Z, Yin H, Wang Y, Wang Y, Li H, Yue L. β-d-glucan from Antrodia Camphorata ameliorates LPS-induced inflammation and ROS production in human hepatocytes. International Journal of Biological Macromolecules 2017;104:768-77. [DOI: 10.1016/j.ijbiomac.2017.05.191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
209 Lang S, Kütting F, Staub A, Schramowski J, Schramm C, Kasper P, Goeser T, Steffen HM, Demir M. Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2017;29:1235-40. [PMID: 28885276 DOI: 10.1097/MEG.0000000000000977] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
210 Pellicelli AM, Vignally P, Messina V, Izzi A, Mazzoni E, Barlattani A, Bacca D, Romano M, Mecenate F, Stroffolini T, Furlan C, Picardi A, Gentilucci UV, Gulminetti R, Bonaventura ME, Villani R, D’ambrosio C, Paffetti A, Mastropietro C, Marignani M, Fondacaro L, Cerasari G, Andreoli A, Barbarini G. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology 2014;13:376-85. [DOI: 10.1016/s1665-2681(19)30844-0] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
211 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
212 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
213 Krishnan G, Subramaniyan J, Chengalvarayan Subramani P, Muralidharan B, Thiruvengadam D. Hesperetin conjugated PEGylated gold nanoparticles exploring the potential role in anti-inflammation and anti-proliferation during diethylnitrosamine-induced hepatocarcinogenesis in rats. Asian J Pharm Sci 2017;12:442-55. [PMID: 32104357 DOI: 10.1016/j.ajps.2017.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
214 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
215 Ferreira SC, Chachá SG, Souza FF, Teixeira AC, Santana RC, Villanova MG, Zucoloto S, Ramalho LN, Perdoná GS, Passos AD, Martinelli AL. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Annals of Hepatology 2014;13:762-70. [DOI: 10.1016/s1665-2681(19)30978-0] [Cited by in Crossref: 17] [Article Influence: 2.4] [Reference Citation Analysis]
216 Meroni M, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? Int J Mol Sci. 2019;20. [PMID: 31540133 DOI: 10.3390/ijms20184568] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 19.5] [Reference Citation Analysis]
217 Liu F, Wang X, Wu G, Chen L, Hu P, Ren H, Hu H. Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One 2015;10:e0142457. [PMID: 26556483 DOI: 10.1371/journal.pone.0142457] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
218 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
219 Ning BF, Ding J, Liu J, Yin C, Xu WP, Cong WM, Zhang Q, Chen F, Han T, Deng X. Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression. Hepatology. 2014;60:1607-1619. [PMID: 24752868 DOI: 10.1002/hep.27177] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
220 Im C, Cho JY, Han H, Yoon Y, Choi Y, Jang JY, Choi H, Jang JS, Kwon SU, Kim H. Laparoscopic left lateral sectionectomy in patients with histologically confirmed cirrhosis. Surgical Oncology 2016;25:132-8. [DOI: 10.1016/j.suronc.2016.05.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
221 Mahmud N, Shaked A, Olthoff KM, Goldberg DS. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease. Liver Transpl 2019;25:388-98. [PMID: 30362249 DOI: 10.1002/lt.25363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
222 Feng X, Tan W, Cheng S, Wang H, Ye S, Yu C, He Y, Zeng J, Cen J, Hu J, Zheng R, Zhou Y. Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-κB pathway. DNA Cell Biol 2015;34:470-80. [PMID: 25974152 DOI: 10.1089/dna.2014.2760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
223 Julien J, Ayer T, Bethea ED, Tapper EB, Chhatwal J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study.Lancet Public Health. 2020;5:e316-e323. [PMID: 32504584 DOI: 10.1016/S2468-2667(20)30062-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 15.0] [Reference Citation Analysis]
224 Liapi E, Geschwind JF. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci 2010;17:405-6. [PMID: 19890602 DOI: 10.1007/s00534-009-0236-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
225 Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev. 2010;3:178-185. [PMID: 20716942 DOI: 10.4161/oxim.3.3.12288] [Cited by in Crossref: 163] [Cited by in F6Publishing: 134] [Article Influence: 14.8] [Reference Citation Analysis]
226 Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-82. [PMID: 26079399 DOI: 10.1002/cncr.29528] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
227 Montagnana M, Danese E, Lippi G. Squamous cell carcinoma antigen in hepatocellular carcinoma: Ready for the prime time? Clin Chim Acta. 2015;445:161-166. [PMID: 25840050 DOI: 10.1016/j.cca.2015.03.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
228 Cassim S, Raymond VA, Dehbidi-Assadzadeh L, Lapierre P, Bilodeau M. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle 2018;17:903-16. [PMID: 29633904 DOI: 10.1080/15384101.2018.1460023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
229 Shen A, Liu M, Zheng D, Chen Q, Wu Z. Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:142-54. [PMID: 31303533 DOI: 10.1016/j.clinre.2019.06.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
230 Fan M, Qian N, Dai G. Expression and prognostic significance of doublecortin-like kinase 1 in patients with hepatocellular carcinoma. Oncol Lett 2017;14:7529-37. [PMID: 29344199 DOI: 10.3892/ol.2017.7082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
231 Han P, Sun D, Yang J. Interaction between periodontitis and liver diseases. Biomed Rep 2016;5:267-76. [PMID: 27588170 DOI: 10.3892/br.2016.718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
232 Hu CC, Weng CH, Hua MC, Chang PH, Lin CL, Chen YT, Chien CH, Lin ST, Chien RN. New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy. J Interferon Cytokine Res 2020;40:82-91. [PMID: 31800346 DOI: 10.1089/jir.2019.0103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Kang YM, Kim YJ, Park JY, Lee WJ, Jung CH. Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013. Cardiovasc Diabetol 2016;15:131. [PMID: 27618811 DOI: 10.1186/s12933-016-0451-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
234 Flisiak R, Halota W, Jaroszewicz J, Juszczyk J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M; Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46. [PMID: 28856289 DOI: 10.5114/ceh.2017.67626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
235 Wang CC, Tseng KC, Tzeng IS, Kao JH. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc 2021;120:965-73. [PMID: 33129621 DOI: 10.1016/j.jfma.2020.10.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
236 Wei MT, Le MH, Landis C, Trinh H, Wong G, Le A, Zhang J, Cheung R, Nguyen MH. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. J Med Virol 2021. [PMID: 34219250 DOI: 10.1002/jmv.27168] [Reference Citation Analysis]
237 Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy. J Gastroenterol Hepatol. 2014;29:137-143. [PMID: 24117602 DOI: 10.1111/jgh.12401] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
238 Martin AP. Management of hepatocellular carcinoma in the age of liver transplantation. Int J Surg 2009;7:324-9. [PMID: 19643691 DOI: 10.1016/j.ijsu.2008.12.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
239 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
240 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
241 Ohta A, Sitkovsky M. Methylxanthines, inflammation, and cancer: fundamental mechanisms. Handb Exp Pharmacol 2011;:469-81. [PMID: 20859809 DOI: 10.1007/978-3-642-13443-2_19] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
242 Blaschke EM, Rao VL, Xiong L, Te HS, Hart J, Reddy KG, Oto A. Multiphase Multi–Detector Row Computed Tomography Imaging Characteristics of Large (>5 cm) Focal Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2016;40:493-7. [DOI: 10.1097/rct.0000000000000379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
243 Deng L, Gui X, Xiong Y, Gao S, Yang R, Rong Y, Hu J, Yan Y. End-stage liver disease: Prevalence, risk factors and clinical characteristics in a cohort of HIV-HCV coinfected Han Chinese. Clinics and Research in Hepatology and Gastroenterology 2012;36:574-82. [DOI: 10.1016/j.clinre.2012.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
244 Arora A, Sharma P, Tyagi P, Singla V, Arora V, Bansal N, Toshniwal J, Kumar A. Hepatitis B Virus Infection can Cause Hepatocellular Carcinoma in Less Advanced Liver Cirrhosis: A Comparative Study of 142 Patients from North India. J Clin Exp Hepatol 2013;3:288-95. [PMID: 25755516 DOI: 10.1016/j.jceh.2013.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
245 Wang CC, Tsai MC, Peng CM, Lee HL, Chen HY, Yang TW, Sung WW, Lin CC. Favorable liver cancer mortality-to-incidence ratios of countries with high health expenditure.Eur J Gastroenterol Hepatol. 2017;29:1397-1401. [PMID: 29023320 DOI: 10.1097/MEG.0000000000000969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
246 Cheng X, Zhong F, He K, Sun S, Chen H, Zhou J. EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells. Oncol Lett 2016;12:3739-48. [PMID: 27895725 DOI: 10.3892/ol.2016.5178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
247 Jim MA, Perdue DG, Richardson LC, Espey DK, Redd JT, Martin HJ, Kwong SL, Kelly JJ, Henderson JA, Ahmed F. Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer. 2008;113:1244-1255. [PMID: 18720380 DOI: 10.1002/cncr.23728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
248 Chapman T, Dubinsky T, Barr RG. Ultrasound Elastography of the Liver: What the Clinician Needs to Know: Ultrasound Elastography of the Liver. J Ultrasound Med 2017;36:1293-304. [DOI: 10.7863/ultra.16.08001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303-1310. [PMID: 16729298 DOI: 10.1002/hep.21176] [Cited by in Crossref: 396] [Cited by in F6Publishing: 347] [Article Influence: 26.4] [Reference Citation Analysis]
250 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
251 Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, Crossey MM, Taylor-Robinson SD. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 2014;6:783-92. [PMID: 25429316 DOI: 10.4254/wjh.v6.i11.783] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
252 Stickel F, Hampe J, Trépo E, Datz C, Romeo S. PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. Hepatobiliary Surg Nutr. 2015;4:152-160. [PMID: 26151055 DOI: 10.3978/j.issn.2304-3881.2014.11.04] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
253 Kim DJ, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. Cancers (Basel). 2019;11. [PMID: 31590436 DOI: 10.3390/cancers11101497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
254 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
255 Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis. Cancer Biol Med 2018;15:124-36. [PMID: 29951337 DOI: 10.20892/j.issn.2095-3941.2018.0018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
256 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol. 2016;22:1497-1512. [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
257 Lee WP, Lan KH, Li CP, Chao Y, Lin HC, Lee SD. Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. Biochim Biophys Acta 2016;1862:837-49. [PMID: 26791804 DOI: 10.1016/j.bbadis.2015.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
258 Perrillo RP. Therapy of hepatitis B — Viral suppression or eradication? Hepatology 2006;43:S182-93. [DOI: 10.1002/hep.20970] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
259 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 33.3] [Reference Citation Analysis]
260 Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2020:S1590-8658(20)30997-X. [PMID: 33214063 DOI: 10.1016/j.dld.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Kwon OS, Jung YK, Bae KS, Kim JH, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study. Alcohol 2012;46:537-41. [PMID: 22572059 DOI: 10.1016/j.alcohol.2012.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
262 Goto T, Dohmen T, Miura K, Ohshima S, Yoneyama K, Shibuya T, Kataoka E, Segawa D, Sato W, Anezaki Y, Ishii H, Kon D, Yamada I, Kamada K, Ohnishi H. Skull metastasis from hepatocellular carcinoma with chronic hepatitis B. World J Gastrointest Oncol 2010;2:165-8. [PMID: 21160825 DOI: 10.4251/wjgo.v2.i3.165] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
263 Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J. 2006;82:507-515. [PMID: 16891440 DOI: 10.1136/pgmj.2006.047431] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
264 Simão A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN, Carvalho A. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol 2015;15:73. [PMID: 26122937 DOI: 10.1186/s12876-015-0307-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
265 You Y, Zheng Q, Dong Y, Wang Y, Zhang L, Xue T, Xie X, Hu C, Wang Z, Chen R, Wang Y, Cui J, Ren Z. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway. PLoS One 2015;10:e0134243. [PMID: 26280346 DOI: 10.1371/journal.pone.0134243] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
266 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
267 Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:277-87. [PMID: 30309638 DOI: 10.1016/j.semradonc.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
268 Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol. 2011;17:914-921. [PMID: 21412500 DOI: 10.3748/wjg.v17.i7.914] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
269 Andreana L, Isgrò G, Pleguezuelo M, Germani G, Burroughs AK. Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol 2009;1:48-61. [PMID: 21160965 DOI: 10.4254/wjh.v1.i1.48] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
270 Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Sezaki H. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol. 2006;44:1089-1097. [PMID: 16618514 DOI: 10.1016/j.jhep.2006.02.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
271 Tsai C, Huang K, Chen H, Zhan B, Lai Y, Lee F, Lin C, Ho Y, Chao Y, Su Y, Jane S, Chen Y, Hsu C, Li P, Hsu H, Suzuki Y, Sugano S, Lin J. Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. J Biomed Sci 2006;13:241-9. [DOI: 10.1007/s11373-005-9062-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
272 Ozturk K, Soylu E, Yazici Z, Ozkaya G, Savci G. Differentiation of hepatocellular carcinoma from non-hepatocellular malignant tumours of liver by chemical-shift MRI at 3 T. Clin Radiol 2019;74:797-804. [PMID: 31300210 DOI: 10.1016/j.crad.2019.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Zarski J, David-tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret M, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-thoraval F, Nahon P. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2020;44:524-31. [DOI: 10.1016/j.clinre.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62:1421-1430. [PMID: 23764929 DOI: 10.1007/s00262-013-1447-1] [Cited by in Crossref: 156] [Cited by in F6Publishing: 139] [Article Influence: 19.5] [Reference Citation Analysis]
275 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
276 Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245:36-43. [PMID: 17197963 DOI: 10.1097/01.sla.0000231758.07868.71.] [Reference Citation Analysis]
277 Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: a review of current literature. World J Gastroenterol. 2008;14:6915-6923. [PMID: 19058325 DOI: 10.3748/wjg.14.6915] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
278 Rahat B, Kiran M, Saxena R, Chawla YK, Sharma RR, Kaur J. Microsomal Epoxide Hydrolase Polymorphisms and Haplotypes as Determinants of Hepatitis B Virusand Hepatitis C Virus-related Liver Disease in Indian Population. J Clin Exp Hepatol 2012;2:104-11. [PMID: 25755418 DOI: 10.1016/S0973-6883(12)60097-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
279 Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: A systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575-583. [PMID: 16899323 DOI: 10.1016/j.jhep.2006.04.007] [Cited by in Crossref: 134] [Cited by in F6Publishing: 107] [Article Influence: 8.9] [Reference Citation Analysis]
280 Khazaei S, Karami M, Ayubi E, Mohammadbeigi A, Hasanbeigi A, Mansori K, Mir-Shekar MR. Trends in epidemiology of Hepatitis B and C Infections in Ilam Province: National Notifiable Diseases Surveillance System data. Caspian J Intern Med 2018;9:16-21. [PMID: 29387314 DOI: 10.22088/cjim.9.1.16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
281 Kuriakose M, Ittyachen AM. An Investigation into the High Prevalence of Hepatitis B in a Rural Area of Kerala State, India: Hypothesis on Chrysops sp. (Diptera: Tabanidae) Transmission. Biomed Res Int 2018;2018:4612472. [PMID: 29984234 DOI: 10.1155/2018/4612472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
282 Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, Chen MS. Radiofrequency ablation vs hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262:1022-1033. [PMID: 22357902 DOI: 10.1148/radiol.11110817] [Cited by in Crossref: 141] [Cited by in F6Publishing: 112] [Article Influence: 15.7] [Reference Citation Analysis]
283 Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol 2011;35:455-64. [PMID: 21435968 DOI: 10.1016/j.clinre.2011.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
284 Cohn A, Aronsohn A. HCV Therapy: Treat now or wait? Curr Hepatitis Rep 2013;12:7-12. [DOI: 10.1007/s11901-013-0163-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
285 Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35:2203-2217. [PMID: 26123841 DOI: 10.1111/liv.12903] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
286 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
287 Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018;155:1436-1450.e6. [PMID: 30031138 DOI: 10.1053/j.gastro.2018.07.015] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 33.0] [Reference Citation Analysis]
288 Kalasekar SM, Kotiyal S, Conley C, Phan C, Young A, Evason KJ. Heterogeneous beta-catenin activation is sufficient to cause hepatocellular carcinoma in zebrafish. Biol Open 2019;8:bio047829. [PMID: 31575545 DOI: 10.1242/bio.047829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
289 Lee SA, Kim KJ, Kim DW, Kim BJ. Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients. J Clin Microbiol 2013;51:3928-36. [PMID: 24025913 DOI: 10.1128/JCM.01505-13] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
290 Tu T, Budzinska MA, Shackel NA, Jilbert AR. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. Liver Int 2015;35:1786-800. [PMID: 25640596 DOI: 10.1111/liv.12773] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
291 Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-18. [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213] [Cited by in Crossref: 673] [Cited by in F6Publishing: 622] [Article Influence: 67.3] [Reference Citation Analysis]
292 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, Kudo M. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84 Suppl 1:43-49. [PMID: 22156485 DOI: 10.1159/000333212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
293 Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
294 Qiu L, Tang Q, Li G, Chen K. Long non-coding RNAs as biomarkers and therapeutic targets: Recent insights into hepatocellular carcinoma. Life Sci 2017;191:273-82. [PMID: 28987633 DOI: 10.1016/j.lfs.2017.10.007] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 16.0] [Reference Citation Analysis]
295 Iyer SC, Gopal A, Halagowder D. Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem 2015;407:223-37. [PMID: 26104578 DOI: 10.1007/s11010-015-2471-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
296 Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273:88-98. [PMID: 24893048 DOI: 10.1148/radiol.14132592] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
297 Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, Hayashi N. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008;99:1643-1649. [PMID: 18754878 DOI: 10.1111/j.1349-7006.2008.00859.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
298 Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, Fumolo E, Bignulin S, Cmet S, Minisini R, Pirisi M, Toniutto P. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol 2010;16:3016-24. [PMID: 20572305 DOI: 10.3748/wjg.v16.i24.3016] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
299 Dalwadi DA, Torrens L, Abril-Fornaguera J, Pinyol R, Willoughby C, Posey J, Llovet JM, Lanciault C, Russell DW, Grompe M, Naugler WE. Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Mol Ther 2021;29:680-90. [PMID: 33554867 DOI: 10.1016/j.ymthe.2020.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
300 Ryu SH, Fan X, Xu Y, Elbaz T, Zekri AN, Abdelaziz AO, Di Bisceglie AM. Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. J Med Virol 2009;81:844-7. [DOI: 10.1002/jmv.21451] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
301 Chang KC, Ye YH, Wu CK, Lin MT, Tsai MC, Tseng PL, Hu TH. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. J Formos Med Assoc. 2018;117:1011-1018. [PMID: 29254684 DOI: 10.1016/j.jfma.2017.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
302 Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2008;17:1963-74. [DOI: 10.1517/13543780802535760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
303 Rude MK, Crippin JS. Liver transplantation for hepatocellular carcinoma. Curr Gastroenterol Rep 2015;17:11. [PMID: 25740250 DOI: 10.1007/s11894-015-0435-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
304 Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prev Res (Phila) 2020;13:497-508. [PMID: 32253266 DOI: 10.1158/1940-6207.CAPR-19-0383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
305 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020;26:2931-47. [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
306 Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, Borge M. Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. Angiology 2012;63:206-12. [PMID: 21733955 DOI: 10.1177/0003319711411705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
307 Sultan A, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2020;14:1007-11. [PMID: 32730120 DOI: 10.1080/17474124.2020.1802246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 De Minicis S, Brenner DA. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J Gastroenterol Hepatol. 2008;23 Suppl 1:S98-S103. [PMID: 18336675 DOI: 10.1111/j.1440-1746.2007.05277.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
309 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015;21:10262-73. [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
310 Medhi S, Sarma MP, Asim M, Kar P. Genetic variants of heat shock protein A1L2437 and A1B1267 as possible risk factors for hepatocellular carcinoma in India. J Viral Hepat 2013;20:e141-7. [PMID: 23490384 DOI: 10.1111/jvh.12021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
311 Zhang S, Liu Z, Wu D, Chen L, Xie L. Single-Cell RNA-Seq Analysis Reveals Microenvironmental Infiltration of Plasma Cells and Hepatocytic Prognostic Markers in HCC With Cirrhosis. Front Oncol 2020;10:596318. [PMID: 33224891 DOI: 10.3389/fonc.2020.596318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
312 Wu MS, Kuo YP, Lo YC, Tsai DJ, Lai CY, Chuang TH, Lin SY, Tsai WT, Chung PJ, Yu GY. Type I Interferon Signaling Accelerates Liver Regeneration by Metabolic Modulation in Noninfectious Conditions. Am J Pathol 2021;191:1036-48. [PMID: 33753025 DOI: 10.1016/j.ajpath.2021.03.006] [Reference Citation Analysis]
313 Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60-66. [PMID: 18417044 DOI: 10.1007/s11894-008-0010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
314 Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, Wei L. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer. 2008;123:998-1004. [PMID: 18546260 DOI: 10.1002/ijc.23650] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
315 Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Ohkawara Y, Yamaguchi K, Minami M, Okanoue T. Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:1926-1932. [PMID: 22563173 DOI: 10.3748/wjg.v18.i16.1926] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
316 de la Monte SM, Yeon JE, Tong M, Longato L, Chaudhry R, Pang MY, Duan K, Wands JR. Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol. 2008;23:e477-e486. [PMID: 18505416 DOI: 10.1111/j.1440-1746.2008.05339.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
317 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
318 de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190-1200. [PMID: 26146815 DOI: 10.1002/hep.27969] [Cited by in Crossref: 230] [Cited by in F6Publishing: 221] [Article Influence: 46.0] [Reference Citation Analysis]
319 Lee SA, Lee SY, Choi YM, Kim H, Kim BJ. Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World J Gastroenterol 2018;24:1084-92. [PMID: 29563753 DOI: 10.3748/wjg.v24.i10.1084] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
320 Hayashi T, Ogawa E, Furusyo N, Murata M, Hayashi J. Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. Infect Agent Cancer 2016;11:9. [PMID: 26913058 DOI: 10.1186/s13027-016-0056-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
321 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
322 Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-476. [PMID: 30982722 DOI: 10.1016/s2468-1253(19)30042-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 21.5] [Reference Citation Analysis]
323 Oramasionwu CU, Brown CM, Ryan L, Lawson KA, Hunter JM, Frei CR. HIV/AIDS disparities: the mounting epidemic plaguing US blacks. J Natl Med Assoc 2009;101:1196-204. [PMID: 20070007 DOI: 10.1016/s0027-9684(15)31130-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
324 Sufleţel RT, Melincovici CS, Gheban BA, Toader Z, Mihu CM. Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom J Morphol Embryol 2020;61:615-42. [PMID: 33817704 DOI: 10.47162/RJME.61.3.01] [Reference Citation Analysis]
325 Kew MC. Hepatitis C virus-induced hepatocellular carcinoma in sub-Saharan Africa. J Afr Cancer 2013;5:169-74. [DOI: 10.1007/s12558-013-0275-8] [Reference Citation Analysis]
326 Singh MK, Das BK, Choudhary S, Gupta D, Patil UK. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother 2018;106:991-1002. [PMID: 30119271 DOI: 10.1016/j.biopha.2018.06.095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
327 Jackson WC, Tang M, Maurino C, Mendiratta-Lala M, Parikh ND, Matuszak MM, Dow JS, Cao Y, Mayo CS, Ten Haken RK, Schipper MJ, Cuneo KC, Owen D, Lawrence TS. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease. Int J Radiat Oncol Biol Phys 2021;109:212-9. [PMID: 32853708 DOI: 10.1016/j.ijrobp.2020.08.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29:385-395. [PMID: 23768703 DOI: 10.1016/j.kjms.2012.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
329 Park SH, Kim B. Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. J Liver Cancer 2020;20:25-31. [DOI: 10.17998/jlc.20.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Laroia ST, Bhadoria AS, Venigalla Y, Chibber GK, Bihari C, Rastogi A, Sarin SK. Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. Eur J Radiol Open 2016;3:162-71. [PMID: 27504474 DOI: 10.1016/j.ejro.2016.05.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
331 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 38.8] [Reference Citation Analysis]
332 Lui HF. Screening for hepatocellular carcinoma. Int J Hepatol 2011;2011:363151. [PMID: 22028976 DOI: 10.4061/2011/363151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
333 Maylin S, Laouénan C, Martinot-peignoux M, Panhard X, Lapalus M, Nicolas-chanoine MH, Bedossa P, Asselah T, Marcellin P. Role of hepatic HCV–RNA level on the severity of chronic hepatitis C and response to antiviral therapy. Journal of Clinical Virology 2012;53:43-7. [DOI: 10.1016/j.jcv.2011.09.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
334 Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One. 2013;8:e71262. [PMID: 23936497 DOI: 10.1371/journal.pone.0071262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
335 Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012;18:6398-408. [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
336 Imperial JC. Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. Expert Rev Gastroenterol Hepatol 2010;4:355-64. [PMID: 20528122 DOI: 10.1586/egh.10.26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
337 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013;5:311-322. [PMID: 23805355 DOI: 10.4254/wjh.v5.i6.311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
338 Yano Y, Azuma T, Hayashi Y. Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics. World J Hepatol. 2015;7:583-592. [PMID: 25848482 DOI: 10.4254/wjh.v7.i3.583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
339 Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200-207. [PMID: 18086507 DOI: 10.1016/j.jhep.2007.09.010] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
340 Aliyu A, Shaari MR, Ahmad Sayuti NS, Reduan MFH, Sithambaram S, Noordin MM, Shaari K, Hamzah H. Subacute Oral Administration of Clinacanthus nutans Ethanolic Leaf Extract Induced Liver and Kidney Toxicities in ICR Mice. Molecules 2020;25:E2631. [PMID: 32517000 DOI: 10.3390/molecules25112631] [Reference Citation Analysis]
341 Muhanna N, Doron S, Abu-tair L, Zayyad H, Mahamid M, Amer J, Safadi R. Early fibrosis inhibits hepatocellular carcinoma mediated by free radical effects. Mitochondrion 2013;13:391-8. [DOI: 10.1016/j.mito.2013.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
342 Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Hsu PI, Wu DC, Chuah SK, Hsu CN. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:E2655. [PMID: 30486324 DOI: 10.3390/ijerph15122655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
343 Ma J, Sanda M, Wei R, Zhang L, Goldman R. Quantitative analysis of core fucosylation of serum proteins in liver diseases by LC-MS-MRM. J Proteomics 2018;189:67-74. [PMID: 29427759 DOI: 10.1016/j.jprot.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
344 Zhang X, Ye ZH, Liang HW, Ren FH, Li P, Dang YW, Chen G. Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study. FEBS Open Bio 2017;7:504-21. [PMID: 28396836 DOI: 10.1002/2211-5463.12198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
345 Vasuri F, Fittipaldi S, Giunchi F, Monica M, Ravaioli M, Degiovanni A, Bonora S, Golfieri R, Bolondi L, Grigioni WF, Pasquinelli G, D'Errico-Grigioni A. Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers. J Clin Pathol 2016;69:102-8. [PMID: 26243063 DOI: 10.1136/jclinpath-2015-203028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
346 Faber W, Stockmann M, Schirmer C, Möllerarnd A, Denecke T, Bahra M, Klein F, Schott E, Neuhaus P, Seehofer D. Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol. 2014;40:208-213. [PMID: 24275202 DOI: 10.1016/j.ejso.2013.10.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
347 Jalal PJ, Urbanowicz RA, Horncastle E, Pathak M, Goddard C, Saeed A, Mason CP, Ball JK, Irving WL, McClure CP, King BJ, Tarr AW. Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. J Med Microbiol 2019;68:642-8. [PMID: 30747617 DOI: 10.1099/jmm.0.000935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Roth CG, Mitchell DG. Hepatocellular carcinoma and other hepatic malignancies: MR imaging. Radiol Clin North Am. 2014;52:683-707. [PMID: 24889167 DOI: 10.1016/j.rcl.2014.02.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
349 Kovac JD, Milovanovic T, Dugalic V, Dumic I. Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma. World J Gastroenterol 2020;26:2012-29. [PMID: 32536771 DOI: 10.3748/wjg.v26.i17.2012] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Williams G. Chemicals with Carcinogenic Activity in Rodent Liver. Comprehensive Toxicology. Elsevier; 2010. pp. 221-50. [DOI: 10.1016/b978-0-08-046884-6.01009-5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
351 Mukhopadhyaya A. Hepatitis C in India. J Biosci. 2008;33:465-473. [PMID: 19208972 DOI: 10.4103/1947-2714.103325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
352 Tsai IT, Wang CP, Yu TH, Lu YC, Lin CW, Lu LF, Wu CC, Chung FM, Lee YJ, Hung WC, Hsu CC. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2017;90:54-59. [PMID: 27770715 DOI: 10.1016/j.cyto.2016.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
353 Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, Nistor GI, Cao W, Chen C, Dillman RO. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111:862-7. [PMID: 25873455 DOI: 10.1002/jso.23897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
354 Suhail M, Abdel-Hafiz H, Ali A, Fatima K, Damanhouri GA, Azhar E, Chaudhary AG, Qadri I. Potential mechanisms of hepatitis B virus induced liver injury. World J Gastroenterol 2014;20:12462-72. [PMID: 25253946 DOI: 10.3748/wjg.v20.i35.12462] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
355 Ding ZY, Jin GN, Liang HF, Wang W, Chen WX, Datta PK, Zhang MZ, Zhang B, Chen XP. Transforming growth factor β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling. Cell Signal 2013;25:1981-92. [PMID: 23727026 DOI: 10.1016/j.cellsig.2013.05.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
356 Pang M, Teng Y, Huang J, Yuan Y, Lin F, Xiong C. Substrate stiffness promotes latent TGF-β1 activation in hepatocellular carcinoma. Biochem Biophys Res Commun 2017;483:553-8. [PMID: 28025149 DOI: 10.1016/j.bbrc.2016.12.107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
357 Costentin C, Ganne-Carrié N, Rousseau B, Gérolami R, Barbare JC. [Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017]. Bull Cancer 2017;104:752-61. [PMID: 28751065 DOI: 10.1016/j.bulcan.2017.06.008] [Reference Citation Analysis]
358 van den Bos IC, Hussain SM, Dwarkasing RS, Hop WC, Zondervan PE, de Man RA, IJzermans JN, Walker CW, Krestin GP. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging. 2007;26:1548-1555. [PMID: 17968956 DOI: 10.1002/jmri.21046] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
359 Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int 2017;37:802-8. [DOI: 10.1111/liv.13390] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
360 Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects. Diagn Interv Imaging. 2014;95:705-708. [PMID: 24768454 DOI: 10.1016/j.diii.2014.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
361 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
362 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
363 Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci 2013;92:3-9. [PMID: 23123447 DOI: 10.1016/j.lfs.2012.10.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
364 Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181. [PMID: 16447285 DOI: 10.1002/hep.20956] [Cited by in Crossref: 333] [Cited by in F6Publishing: 287] [Article Influence: 22.2] [Reference Citation Analysis]
365 Moon H, Cho K, Shin S, Kim DY, Han KH, Ro SW. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. Int J Mol Sci. 2019;20. [PMID: 30700007 DOI: 10.3390/ijms20030581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
366 Rao D, Guan S, Huang J, Chang Q, Duan S. miR-425-5p Acts as a Molecular Marker and Promoted Proliferation, Migration by Targeting RNF11 in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:6530973. [PMID: 33123581 DOI: 10.1155/2020/6530973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
367 Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37:622-627. [PMID: 15996630 DOI: 10.1016/j.dld.2005.02.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
368 Molla S, Munshea A, Nibret E. Seroprevalence of hepatitis B surface antigen and anti HCV antibody and its associated risk factors among pregnant women attending maternity ward of Felege Hiwot Referral Hospital, northwest Ethiopia: a cross-sectional study. Virol J 2015;12:204. [PMID: 26626263 DOI: 10.1186/s12985-015-0437-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
369 Danielsson Borssén Å, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, Nyhlin N, Hultcrantz R, Sangfelt P, Weiland O, Lindgren S, Verbaan H, Werner M. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015;50:217-23. [PMID: 25483724 DOI: 10.3109/00365521.2014.983154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
370 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 571] [Article Influence: 78.1] [Reference Citation Analysis]
371 Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, Hisamochi A, Torimura T, Sata M; Autoimmune Hepatitis Study Group. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012;47:569-576. [PMID: 22187167 DOI: 10.1007/s00535-011-0519-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
372 Trad D, Bibani N, Sabbah M, Elloumi H, Gargouri D, Ouakaa A, Kharrat J. Known, new and emerging risk factors of hepatocellular carcinoma (review). La Presse Médicale 2017;46:1000-7. [DOI: 10.1016/j.lpm.2017.09.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
373 Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012;109:352-358. [PMID: 22675406 DOI: 10.3238/arztebl.2012.0352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
374 Saran U, Humar B, Kolly P, Dufour J. Hepatocellular carcinoma and lifestyles. Journal of Hepatology 2016;64:203-14. [DOI: 10.1016/j.jhep.2015.08.028] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
375 Patel J, Yopp A, Waljee AK, Singal AG. Development and Internal Validation of a Model for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. J Clin Gastroenterol 2016;50:175-9. [PMID: 26125462 DOI: 10.1097/MCG.0000000000000377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
376 Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am. 2010;18:421-450, x. [PMID: 21094448 DOI: 10.1016/j.mric.2010.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
377 Stroffolini T, Sagnelli E, Sagnelli C, Morisco F, Babudieri S, Furlan C, Pirisi M, Russello M, Smedile A, Pisaturo M, Almasio PL. Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy. Infection. 2019;. [PMID: 31028627 DOI: 10.1007/s15010-019-01308-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
378 Forsgren MF, Nasr P, Karlsson M, Dahlström N, Norén B, Ignatova S, Sinkus R, Cedersund G, Leinhard OD, Ekstedt M, Kechagias S, Lundberg P. Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scand J Gastroenterol 2020;55:848-59. [PMID: 32684060 DOI: 10.1080/00365521.2020.1786599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
379 Wang Y, Wang M, Li H, Chen K, Zeng H, Bi X, Zhu Z, Jiao Y, Wang Y, Zhu J, Zhao H, Liu X, Dai C, Fan C, Zhao C, Guo D, Zhao H, Zhou J, Wang D, Wu Z, Zhao X, Cui W, Zhang X, Cai J, Chen W, Qu C. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. Chin J Cancer Res 2021;33:352-63. [PMID: 34321832 DOI: 10.21147/j.issn.1000-9604.2021.03.07] [Reference Citation Analysis]
380 Suh B, Park S, Shin DW, Yun JM, Yang HK, Yu SJ, Shin CI, Kim JS, Ahn E, Lee H, Park JH, Cho B. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 2015;61:1261-1268. [PMID: 25502481 DOI: 10.1002/hep.27654] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
381 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
382 Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treat Res 2019;177:231-50. [PMID: 30523627 DOI: 10.1007/978-3-030-03502-0_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
383 Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013;92:3-9. [PMID: 23123447 DOI: 10.1016/-j.lfs.2012.-10.-009] [Reference Citation Analysis]
384 Shen Y, Li J, Wang SQ, Jiang W. Ambiguous roles of innate lymphoid cells in chronic development of liver diseases. World J Gastroenterol 2018;24:1962-77. [PMID: 29760540 DOI: 10.3748/wjg.v24.i18.1962] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
385 Han H, Desert R, Das S, Song Z, Athavale D, Ge X, Nieto N. Danger signals in liver injury and restoration of homeostasis. J Hepatol 2020;73:933-51. [PMID: 32371195 DOI: 10.1016/j.jhep.2020.04.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
386 Liu YJ, Zhou Y, Yeh MM. Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study. Mol Cytogenet. 2014;7:81. [PMID: 25469175 DOI: 10.1186/s13039-014-0081-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
387 Zhou T, Ye L, Bai Y, Sun A, Cox B, Liu D, Li Y, Liotta D, Snyder JP, Fu H, Huang B. Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog. PLoS One 2014;9:e107876. [PMID: 25268357 DOI: 10.1371/journal.pone.0107876] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
388 Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterol. 2017;4:e000166. [PMID: 29119002 DOI: 10.1136/bmjgast-2017-000166] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
389 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
390 Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17:608. [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
391 Roberts SK, Kemp W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation. J Gastroenterol Hepatol. 2007;22:191-196. [PMID: 17295870 DOI: 10.1111/j.1440-1746.2006.04459.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
392 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
393 Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol 2016;22:7569-78. [PMID: 27672277 DOI: 10.3748/wjg.v22.i33.7569] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
394 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061}] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
395 Zhang R, Jiang Y, Xiao K, Huang X, Wang J, Chen S. Candidate lncRNA–miRNA–mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis. J Cancer Res Clin Oncol 2020;146:87-96. [DOI: 10.1007/s00432-019-03090-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
396 Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16. [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007] [Cited by in Crossref: 637] [Cited by in F6Publishing: 584] [Article Influence: 70.8] [Reference Citation Analysis]
397 Chernyak V, Kim J, Rozenblit AM, Mazzoriol F, Ricci Z. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: The role of laboratory factors. J Magn Reson Imaging 2011;34:301-9. [DOI: 10.1002/jmri.22635] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
398 Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2017;15:746-755.e4. [PMID: 27847278 DOI: 10.1016/j.cgh.2016.10.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
399 Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538. [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013] [Cited by in Crossref: 1610] [Cited by in F6Publishing: 1424] [Article Influence: 107.3] [Reference Citation Analysis]
400 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 313] [Article Influence: 48.4] [Reference Citation Analysis]
401 Kuang P, Zhao W, Su W, Zhang Z, Zhang L, Liu J, Ren G, Yin Z, Wang X. 18β-glycyrrhetinic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell-mediated immunosuppression in mice. Int J Cancer 2013;132:1831-41. [PMID: 22991231 DOI: 10.1002/ijc.27852] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
402 Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterol 2021;21:177. [PMID: 33865328 DOI: 10.1186/s12876-021-01761-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Abdel-lateef EE, Hammam OA, Mahmoud FS, Atta SA, El-sayed MM, Hassenein HI. Induction of apoptosis in HepG2 by Vitex agnus-castus L. leaves extracts and identification of their active chemical constituents by LC-ESI-MS. Asian Pacific Journal of Tropical Disease 2016;6:539-48. [DOI: 10.1016/s2222-1808(16)61084-8] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
404 Drew L. Tipping the balance. Nature 2018;564:S74-5. [PMID: 30568206 DOI: 10.1038/d41586-018-07760-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
405 Fifield BA, Talia J, Stoyanovich C, Elliott MJ, Bakht MK, Basilious A, Samsoondar JP, Curtis M, Stringer KF, Porter LA. Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation. Carcinogenesis 2020;41:850-62. [PMID: 31574533 DOI: 10.1093/carcin/bgz164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014;20:16630-8. [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
407 Zhou Y, Lei X, Wu L, Wu X, Xu D, Li B. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: A systematic review. Surgical Oncology 2014;23:236-42. [DOI: 10.1016/j.suronc.2014.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
408 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol. 2015;7:1708-1717. [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
409 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608. [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005] [Cited by in Crossref: 744] [Cited by in F6Publishing: 635] [Article Influence: 93.0] [Reference Citation Analysis]
410 Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect 2015;21:969-74. [PMID: 26163104 DOI: 10.1016/j.cmi.2015.06.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
411 Hofmann WP, Soriano V, Zeuzem S. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handb Exp Pharmacol 2009;:321-46. [PMID: 19048206 DOI: 10.1007/978-3-540-79086-0_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
412 Yuan L, Luo X, Lu X, Yi B, Chu K, Cai Q, Jiang X. Comparison of clinicopathological characteristics between cirrhotic and non-cirrhotic patients with intrahepatic cholangiocarcinoma: A large-scale retrospective study. Mol Clin Oncol 2017;7:615-22. [PMID: 29046795 DOI: 10.3892/mco.2017.1387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
413 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018;24:3090-100. [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
414 Conti F, Dall'Agata M, Gramenzi A, Biselli M. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med 2015;9:1343-51. [PMID: 26580585 DOI: 10.2217/bmm.15.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
415 Cucchetti A, D'Amico G, Trevisani F, Morelli MC, Vitale A, Pinna AD, Cescon M; from the Special Interest Group on Hepatocellular carcinoma and new anti HCV therapies of the Italian Association for the Study of the Liver (AISF). Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. Dig Liver Dis 2018;50:156-62. [PMID: 29102521 DOI: 10.1016/j.dld.2017.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
416 Tsang JPK, Poon WL, Luk HM, Fung CW, Ching CK, Mak CM, Lam CW, Siu TS, Tam S, Wong VC. Arginase Deficiency With New Phenotype and a Novel Mutation: Contemporary Summary. Pediatric Neurology 2012;47:263-9. [DOI: 10.1016/j.pediatrneurol.2012.06.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
417 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
418 Strathearn LS, Stepanov AI, Font-Burgada J. Inflammation in Primary and Metastatic Liver Tumorigenesis-Under the Influence of Alcohol and High-Fat Diets. Nutrients 2020;12:E933. [PMID: 32230953 DOI: 10.3390/nu12040933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
419 Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51:845-852. [PMID: 19729219 DOI: 10.1016/j.jhep.2009.06.027] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 9.2] [Reference Citation Analysis]
420 Zhang Y, Archer KJ. Bayesian penalized cumulative logit model for high-dimensional data with an ordinal response. Stat Med 2021;40:1453-81. [PMID: 33336826 DOI: 10.1002/sim.8851] [Reference Citation Analysis]
421 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
422 Islam MM, Poly TN, Walther BA, Yang HC, Jack Li YC. Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Cancers (Basel) 2020;12:E671. [PMID: 32183029 DOI: 10.3390/cancers12030671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
423 Mahalingam D, Chelis L, Nizamuddin I, Lee SS, Kakolyris S, Halff G, Washburn K, Attwood K, Fahad I, Grigorieva J, Asmellash S, Meyer K, Oliveira C, Roder H, Roder J, Iyer R. Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test. Cancers (Basel) 2021;13:3109. [PMID: 34206321 DOI: 10.3390/cancers13133109] [Reference Citation Analysis]
424 Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109:1223-1233. [PMID: 24890440 DOI: 10.1038/ajg.2014.145] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
425 Macaluso FS, Calvaruso V, Craxì A. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiol 2015;10:977-88. [PMID: 26059621 DOI: 10.2217/fmb.15.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
426 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
427 Yeh YT, Chang CW, Wei RJ, Wang SN. Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects. Biomed Res Int. 2013;2013:290575. [PMID: 23484104 DOI: 10.1155/2013/290575] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
428 Shehta A, Han H, Yoon Y, Cho JY, Choi Y. Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: 10-year single-center experience. Surg Endosc 2016;30:638-48. [DOI: 10.1007/s00464-015-4253-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
429 Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery. 2010;147:676-685. [PMID: 20004441 DOI: 10.1016/j.surg.2009.10.043] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 7.6] [Reference Citation Analysis]
430 Li Q, Wang C, Wang Y, Sun L, Liu Z, Wang L, Song T, Yao Y, Liu Q, Tu K. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. J Exp Clin Cancer Res 2018;37:231. [PMID: 30231922 DOI: 10.1186/s13046-018-0908-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
431 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
432 Wang H, Cao G, Fu J, Lv G. Hepatitis Viruses and Hepatoma. In: Bast RC, Hait WN, Kufe DW, Weichselbaum RR, Holland JF, Croce CM, Piccart-gebart M, Wang H, Hong WK, Pollock RE, editors. Holland-Frei Cancer Medicine. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 1-6. [DOI: 10.1002/9781119000822.hfcm031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
433 Sun H, Chua MS, Yang D, Tsalenko A, Peter BJ, So S. Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma. Biomark Insights 2008;3:1-18. [PMID: 19578489 DOI: 10.4137/bmi.s595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
434 Hübscher SG. Role of liver biopsy in disorders of iron metabolism. Diagnostic Histopathology 2008;14:577-85. [DOI: 10.1016/j.mpdhp.2008.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
435 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Reference Citation Analysis]
436 Chien J, Liu J, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Yang HI, Chen CJ. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. J Gastroenterol Hepatol 2016;31:1971-7. [PMID: 27118149 DOI: 10.1111/jgh.13422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
437 Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, Won HJ, Lee SJ, Lee HC, Lee YS. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2017;3:456-463. [PMID: 27657493 DOI: 10.1001/jamaoncol.2016.3147] [Cited by in Crossref: 113] [Cited by in F6Publishing: 93] [Article Influence: 28.3] [Reference Citation Analysis]
438 Duan YF, Li XD, Sun DL, Chen XM, An Y, Zhu F. A preliminary study on surgery for hepatocellular carcinoma patients with portal hypertension. Am J Surg. 2015;210:129-133. [PMID: 25457251 DOI: 10.1016/j.amjsurg.2014.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
439 Pinato DJ, Dalla Pria A, Sharma R, Bower M. Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection. AIDS 2017;31:603-11. [DOI: 10.1097/qad.0000000000001422] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
440 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
441 Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T. Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. Gastroenterology 2006;130:1098-106. [DOI: 10.1053/j.gastro.2006.02.016] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
442 Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858. [PMID: 20659285 DOI: 10.1111/j.1365-2036.2010.04414.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
443 Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987-1997. [PMID: 22144108 DOI: 10.1002/hep.24545] [Cited by in Crossref: 212] [Cited by in F6Publishing: 181] [Article Influence: 23.6] [Reference Citation Analysis]
444 Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M. Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma: Data mining of non-HBV/non-HCV-related HCC. Hepatology Research 2011;41:564-71. [DOI: 10.1111/j.1872-034x.2011.00799.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
445 Calvaruso V, Bruix J. Towards personalized screening for hepatocellular carcinoma: Still not there. J Hepatol. 2020;73:1319-1321. [PMID: 32771323 DOI: 10.1016/j.jhep.2020.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
446 Nishitsuji H, Yamamoto H, Shiina R, Harada K, Ujino S, Shimotohno K. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J Vis Exp 2017. [PMID: 28190076 DOI: 10.3791/54849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
447 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021;27:2994-3009. [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
448 Cauble S, Abbas A, Balart L, Bazzano L, Medvedev S, Shores N. United States women receive more curative treatment for hepatocellular carcinoma than men. Dig Dis Sci. 2013;58:2817-2825. [PMID: 23812858 DOI: 10.1007/s10620-013-2731-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
449 Dong Y, Xie X, Wang Z, Hu C, Zheng Q, Wang Y, Chen R, Xue T, Chen J, Gao D. Increasing matrix stiffness upregulates vascular endothelial growth factor expression in hepatocellular carcinoma cells mediated by integrin β1. Biochem Biophys Res Commun. 2014;444:427-432. [PMID: 24472554 DOI: 10.1016/j.bbrc.2014.01.079] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
450 Lin C, Kao J. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45. [DOI: 10.1007/s11373-007-9225-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
451 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016;7:242-55. [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
452 Parsikia A, Campos S, Khanmoradi K, Pang J, Balasubramanian M, Zaki R, Ortiz J. Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With Cirrhosis. Int Surg 2015;100:142-54. [PMID: 25594655 DOI: 10.9738/INTSURG-D-13-00231.1] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
453 Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F; EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-70; quiz 1660, 1671. [PMID: 17555459 DOI: 10.1111/j.1572-0241.2007.01337.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 7.1] [Reference Citation Analysis]
454 Kim YK, Kim Y, Shim SS. Thoracic Complications of Liver Cirrhosis: Radiologic Findings. RadioGraphics 2009;29:825-37. [DOI: 10.1148/rg.293085093] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
455 Sofue K, Yoshikawa T, Ohno Y, Negi N, Inokawa H, Sugihara N, Sugimura K. Improved image quality in abdominal CT in patients who underwent treatment for hepatocellular carcinoma with small metal implants using a raw data-based metal artifact reduction algorithm. Eur Radiol 2017;27:2978-88. [DOI: 10.1007/s00330-016-4660-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
456 Xu X, Yue M, Jiang L, Deng X, Zhang Y, Zhang Y, Zhu D, Xiao W, Zhou Z, Yao W, Kong J, Yu X, Wei J. Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population. Int J Mol Sci 2014;15:9826-43. [PMID: 24897020 DOI: 10.3390/ijms15069826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
457 Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther. 2012;36:104-114. [PMID: 22612303 DOI: 10.1111/j.1365-2036.2012.05145.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
458 Kojima Y, Okudela K, Matsumura M, Omori T, Baba T, Sekine A, Woo T, Umeda S, Takemura T, Mitsui H, Suzuki T, Tateishi Y, Iwasawa T, Arai H, Tajiri M, Ogura T, Kameda Y, Masuda M, Ohashi K. The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. Histopathology 2017;70:568-78. [PMID: 27757985 DOI: 10.1111/his.13103] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
459 Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, Ng IO, Wong CC. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis. 2018;7:44. [PMID: 29799025 DOI: 10.1038/s41389-018-0052-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
460 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
461 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
462 Fattovich G, Llovet JM. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol. 2006;44:1013-1016. [PMID: 16678654 DOI: 10.1016/j.jhep.2006.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
463 Debarry J, Cornberg M, Manns MP. Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Liver Int 2017;37 Suppl 1:67-72. [PMID: 28052625 DOI: 10.1111/liv.13320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
464 Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013;8:e61448. [PMID: 23613855 DOI: 10.1371/journal.pone.0061448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
465 Nischalke HD, Lutz P, Krämer B, Söhne J, Müller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer H, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. Journal of Hepatology 2014;61:1073-9. [DOI: 10.1016/j.jhep.2014.06.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
466 Wang WL, Zhu Y, Cheng JW, Li MX, Xia JM, Hao J, Yu L, Lv Y, Wu Z, Wang B. Major hepatectomy is safe for hepatocellular carcinoma in elderly patients with cirrhosis. Eur J Gastroenterol Hepatol. 2014;26:444-451. [PMID: 24463566 DOI: 10.1097/meg.0000000000000046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
467 Joshi K, Kohli A, Manch R, Gish R. Alcoholic Liver Disease. Clinics in Liver Disease 2016;20:563-80. [DOI: 10.1016/j.cld.2016.02.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
468 Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459-464. [PMID: 18387499 DOI: 10.1016/j.cgh.2008.02.012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 7.8] [Reference Citation Analysis]
469 Sun LM, Lin MC, Lin CL, Liang JA, Jeng LB, Kao CH, Lu CY. Nonalcoholic Cirrhosis Increased Risk of Digestive Tract Malignancies: A Population-Based Cohort Study. Medicine (Baltimore). 2015;94:e2080. [PMID: 26656334 DOI: 10.1097/md.0000000000002080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
470 Maher SG, Reynolds JV. Basic Concepts of Inflammation and its Role in Carcinogenesis. In: Jankowski JAZ, editor. Inflammation and Gastrointestinal Cancers. Berlin: Springer Berlin Heidelberg; 2011. pp. 1-34. [DOI: 10.1007/978-3-642-03503-6_1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
471 Kudo M. Tailor-made therapy for viral hepatitis: recent advances. Digestion 2011;84 Suppl 1:1-4. [PMID: 22156478 DOI: 10.1159/000333207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
472 Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923-928. [PMID: 19303163 DOI: 10.1016/j.jhep.2009.01.014] [Cited by in Crossref: 228] [Cited by in F6Publishing: 182] [Article Influence: 19.0] [Reference Citation Analysis]
473 Cantarini MC, de la Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44:446-457. [PMID: 16871543 DOI: 10.1002/hep.21272] [Cited by in Crossref: 95] [Cited by in F6Publishing: 103] [Article Influence: 6.3] [Reference Citation Analysis]
474 Winters AC, Viramontes M, Buch A, Najarian L, Yum J, Yang L, Saab S. Older Patients With Hepatocellular Carcinoma Are Less Knowledgeable About Survivorship Issues: Outcomes from a Survey-based Study. J Clin Gastroenterol 2021;55:88-92. [PMID: 33060439 DOI: 10.1097/MCG.0000000000001442] [Reference Citation Analysis]
475 Lhewa D, Green EW, Naugler WE. Multidisciplinary Team Management of Hepatocellular Carcinoma Is Standard of Care. Clin Liver Dis. 2020;24:771-787. [PMID: 33012458 DOI: 10.1016/j.cld.2020.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015;27:638-643. [PMID: 25831135 DOI: 10.1097/meg.0000000000000341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 7.4] [Reference Citation Analysis]
477 Lee C, Cheung ST. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31731457 DOI: 10.3390/cancers11111646] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
478 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:800-806. [PMID: 19281869 DOI: 10.1016/j.cgh.2009.02.025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
479 Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20 Suppl 1:S49-S60. [PMID: 17486052 DOI: 10.1038/modpathol.3800682] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
480 Chen S, Guo L, Wang Z, Mao W, Ge Y, Ying X, Fang J, Long Q, Liu Q, Xiang H, Wu C, Fu C, Dong D, Zhang J, Sun J, Tian L, Wang L, Zhou M, Zhang M, Qian M, Liu W, Jiang W, Feng W, Zeng X, Ding X, Lei X, Tolhurst R, Xu L, Wang H, Ziegeweid F, Glenn S, Ji JS, Story M, Yamey G, Tang S. Current situation and progress toward the 2030 health-related Sustainable Development Goals in China: A systematic analysis. PLoS Med 2019;16:e1002975. [PMID: 31743352 DOI: 10.1371/journal.pmed.1002975] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
481 Berendse K, Koot BGP, Klouwer FCC, Engelen M, Roels F, Lacle MM, Nikkels PGJ, Verheij J, Poll-The BT. Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. J Inherit Metab Dis 2019;42:955-65. [PMID: 31150129 DOI: 10.1002/jimd.12132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
482 Sidharthan S, Kottilil S. Mechanisms of alcohol-induced hepatocellular carcinoma. Hepatol Int 2014;8:452-7. [PMID: 25383134 DOI: 10.1007/s12072-013-9494-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
483 Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. Int J Mol Sci 2019;20:E1406. [PMID: 30897788 DOI: 10.3390/ijms20061406] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
484 Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infect Dis (Lond) 2017;49:561-75. [PMID: 28293974 DOI: 10.1080/23744235.2017.1300682] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
485 Giorgio A, Calisti G, Montesarchio L, Scognamiglio U, Matteucci P, Coppola C, Scarano F, Amendola F, Giorgio V. Hepatocellular carcinoma invading portal venous system in cirrhosis: long term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study. Anticancer Res. 2014;34:6785-6790. [PMID: 25368292 DOI: 10.2214/ajr.08.2087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
486 Ohfuji S, Matsuura T, Tamori A, Kubo S, Sasaki S, Kondo K, Ito K, Fukushima W. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan. Dig Dis Sci 2021;66:2118-28. [PMID: 32720018 DOI: 10.1007/s10620-020-06475-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
487 Caviglia JM, Yan J, Jang MK, Gwak GY, Affo S, Yu L, Olinga P, Friedman RA, Chen X, Schwabe RF. MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 2018;67:2414-29. [PMID: 29091291 DOI: 10.1002/hep.29627] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
488 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 255] [Article Influence: 30.3] [Reference Citation Analysis]
489 Mohamed Suhaimi NA, Zhuo L. Imidazolium salt attenuates thioacetamide-induced liver fibrosis in mice by modulating inflammation and oxidative stress. Dig Liver Dis. 2012;44:665-673. [PMID: 22483594 DOI: 10.1016/j.dld.2012.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
490 Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, Aoyagi Y. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 2012;56:381-388. [PMID: 21756848 DOI: 10.1016/j.jhep.2011.06.017] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
491 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
492 Mathew S, Ali A, Abdel-hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution 2014;26:327-39. [DOI: 10.1016/j.meegid.2014.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
493 Li W, Liao X, Ning P, Cao Y, Zhang M, Bu Y, Lv J, Jia Q. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma. BMC Cancer 2019;19:395. [PMID: 31029128 DOI: 10.1186/s12885-019-5603-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
494 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
495 Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated? World J Gastroenterol. 2011;17:5083-5088. [PMID: 22171142 DOI: 10.3748/wjg.v17.i46.5083] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
496 M'Bengue AK, Doumbia M, Denoman SR, Ouattara DN, Adoubi I, Pineau P. A major shift of viral and nutritional risk factors affects the hepatocellular carcinoma risk among Ivorian patients: a preliminary report. Infect Agent Cancer 2015;10:18. [PMID: 26131017 DOI: 10.1186/s13027-015-0013-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
497 Pott LL, Hagemann S, Reis H, Lorenz K, Bracht T, Herold T, Skryabin BV, Megger DA, Kälsch J, Weber F, Sitek B, Baba HA. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC. Oncotarget 2017;8:11950-62. [PMID: 28060762 DOI: 10.18632/oncotarget.14447] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
498 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
499 Cassim S, Bilodeau M, Vincent C, Lapierre P. Novel Immunotherapies for Autoimmune Hepatitis. Front Pediatr 2017;5:8. [PMID: 28184367 DOI: 10.3389/fped.2017.00008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
500 Bartolomeo N, Trerotoli P, Serio G. Progression of liver cirrhosis to HCC: an application of hidden Markov model. BMC Med Res Methodol 2011;11:38. [PMID: 21457586 DOI: 10.1186/1471-2288-11-38] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
501 Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2011;26:960-964. [PMID: 21443660 DOI: 10.1111/j.1440-1746.2011.06723.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
502 Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155-201. [PMID: 23461136 DOI: 10.1016/b978-0-12-405211-6.00006-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
503 Kwok RM, Tran TT. Management of Cirrhotic Patients After Successful HCV Eradication. Curr Treat Options Gastroenterol 2017;15:305-15. [PMID: 28439747 DOI: 10.1007/s11938-017-0134-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
504 Awad T, Thorlund K, Gluud C, Awad T. Cryotherapy for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd007611] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
505 Liu X, Yang L, Tu J, Cai W, Zhang M, Shou Z, Yao Y, Xu Q. microRNA-526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma. Oncotarget 2017;8:87737-49. [PMID: 29152116 DOI: 10.18632/oncotarget.21209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
506 Khan T, Ali M, Khan A, Nisar P, Jan SA, Afridi S, Shinwari ZK. Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects. Biomolecules 2019;10:E47. [PMID: 31892257 DOI: 10.3390/biom10010047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 13.5] [Reference Citation Analysis]
507 Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol 2018;9:546-52. [PMID: 29998020 DOI: 10.21037/jgo.2018.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
508 Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25:439-452. [PMID: 20370723 DOI: 10.1111/j.1440-1746.2009.06207.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 6.7] [Reference Citation Analysis]
509 Okina Y, Sato-Matsubara M, Matsubara T, Daikoku A, Longato L, Rombouts K, Thanh Thuy LT, Ichikawa H, Minamiyama Y, Kadota M, Fujii H, Enomoto M, Ikeda K, Yoshizato K, Pinzani M, Kawada N. TGF-β1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis. J Hepatol 2020;73:882-95. [PMID: 32330605 DOI: 10.1016/j.jhep.2020.03.051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
510 He M, Zhang W, Dong Y, Wang L, Fang T, Tang W, Lv B, Chen G, Yang B, Huang P, Xia J. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res 2017;36:15. [PMID: 28100270 DOI: 10.1186/s13046-017-0490-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
511 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
512 Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2013;2:22-30. [PMID: 24570911 DOI: 10.3978/j.issn.2304-3881.2012.11.03] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
513 Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, Li Z, Wu MC, Feng GS, Xie WF, Wang HY. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology. 2012;56:2255-2267. [PMID: 22898879 DOI: 10.1002/hep.26007] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 18.6] [Reference Citation Analysis]
514 Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61:161-170. [PMID: 24954587 DOI: 10.1002/hep.27274] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
515 K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. Dig Liver Dis 2015;47:296-302. [PMID: 25596930 DOI: 10.1016/j.dld.2014.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
516 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
517 Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104. [DOI: 10.1002/hep.21966] [Cited by in Crossref: 670] [Cited by in F6Publishing: 554] [Article Influence: 47.9] [Reference Citation Analysis]
518 Ramalho M, Matos AP, AlObaidy M, Velloni F, Altun E, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. Radiol Bras. 2017;50:38-47. [PMID: 28298731 DOI: 10.1590/0100-3984.2015.0132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
519 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
520 Fan Y, Ding J, Nguyen S, Liu X, Xu G, Zhou H, Duan N, Yang S, Zern MA, Wu J. Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Oncogene 2016;35:116-24. [DOI: 10.1038/onc.2015.67] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
521 Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis. 2013;17:451-473. [PMID: 23905816 DOI: 10.1016/j.cld.2013.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
522 Kadri H, Blank S, Wang Q, Kim K, Fiel M, Luan W, Hiotis S. Outcomes following liver resection and clinical pathologic characteristics of hepatocellular carcinoma occurring in patients with chronic hepatitis B and minimally fibrotic liver. European Journal of Surgical Oncology (EJSO) 2013;39:1371-6. [DOI: 10.1016/j.ejso.2013.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
523 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
524 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216-254. [PMID: 24133661 DOI: 10.3350/cmh.2013.19.3.216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
525 Sticova E, Jirsa M. ABCB4 disease: Many faces of one gene deficiency. Ann Hepatol 2020;19:126-33. [PMID: 31759867 DOI: 10.1016/j.aohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
526 Aleksic K, Lackner C, Geigl JB, Schwarz M, Auer M, Ulz P, Fischer M, Trajanoski Z, Otte M, Speicher MR. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011;53:895-904. [PMID: 21374661 DOI: 10.1002/hep.24133] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
527 Xu J, Lin Y, Wang YP, Chen YX, Shi B, Lu J, Xie WF. Hepatitis B virus DNA in patients with hepatitis B-related liver cirrhosis with or without hepatocellular carcinomas: a matched case-control study. Journal of Digestive Diseases 2009;10:138-44. [DOI: 10.1111/j.1751-2980.2009.00376.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
528 Lima PH, Fan B, Bérubé J, Cerny M, Olivié D, Giard JM, Beauchemin C, Tang A. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:17-25. [PMID: 30995098 DOI: 10.2214/AJR.18.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
529 Siddiqui IA, Latouche EL, DeWitt MR, Swet JH, Kirks RC, Baker EH, Iannitti DA, Vrochides D, Davalos RV, McKillop IH. Induction of rapid, reproducible hepatic ablations using next-generation, high frequency irreversible electroporation (H-FIRE) in vivo. HPB (Oxford). 2016;18:726-734. [PMID: 27593589 DOI: 10.1016/j.hpb.2016.06.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
530 Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1654-1664. [PMID: 22849701 DOI: 10.1111/j.1440-1746.2012.07232.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
531 Jalal PJ, King BJ, Saeed A, Adedeji Y, Mason CP, Ball JK, Irving WL, McClure CP, Tarr AW. Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection. Virology 2019;530:99-106. [PMID: 30798068 DOI: 10.1016/j.virol.2019.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
532 Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, Kenner L, Kolbe T, Mueller M, Snibson KJ, Heim MH, Moriggl R. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology 2012;55:941-52. [PMID: 22031092 DOI: 10.1002/hep.24765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
533 Jung YW, Kim M, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. J Korean Med Sci 2020;35:e104. [PMID: 32356416 DOI: 10.3346/jkms.2020.35.e104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
534 Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-9280. [PMID: 25071320 DOI: 10.3748/wjg.v20.i28.9270] [Cited by in F6Publishing: 52] [Reference Citation Analysis]
535 Cariello M, Peres C, Zerlotin R, Porru E, Sabbà C, Roda A, Moschetta A. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4-/- Mice. Sci Rep 2017;7:11203. [PMID: 28894223 DOI: 10.1038/s41598-017-11549-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
536 Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Takeshima F, Nakao K. Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells. J Gastroenterol 2012;47:195-202. [PMID: 22038554 DOI: 10.1007/s00535-011-0481-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
537 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
538 Pan X, Li M, Huang L, Mo D, Liang Y, Huang Z, Zhu B, Fang M. CD44, IL-33, and ST2 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility in the Chinese Population. Biomed Res Int 2020;2020:2918517. [PMID: 33062675 DOI: 10.1155/2020/2918517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
539 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
540 Hsiang JC, Bai WW, Raos Z, Stableforth W, Upton A, Selvaratnam S, Gane EJ, Gerred SJ. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand: Cirrhosis outcomes in New Zealand. Intern Med J 2015;45:160-9. [DOI: 10.1111/imj.12624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
541 Marrero CR, Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 2007;38:612-20. [DOI: 10.1016/j.arcmed.2006.09.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
542 Wang Z, Sun L, Wu Y, Xia Q. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016;40:195-202. [PMID: 26299874 DOI: 10.1016/j.clinre.2015.06.022] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
543 Sebastiani G, Walker AP. HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol 2007;13:4673-89. [PMID: 17729389 DOI: 10.3748/wjg.v13.i35.4673] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
544 Sahu B, Pihlajamaa P, Zhang K, Palin K, Ahonen S, Cervera A, Ristimäki A, Aaltonen LA, Hautaniemi S, Taipale J. Human cell transformation by combined lineage conversion and oncogene expression. Oncogene 2021. [PMID: 34302118 DOI: 10.1038/s41388-021-01940-0] [Reference Citation Analysis]
545 Townsend SA, Edgar RG, Ellis PR, Kantas D, Newsome PN, Turner AM. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018;47:877-885. [PMID: 29446109 DOI: 10.1111/apt.14537] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
546 Hofmann WP, Mauss S, Lutz T, Schober A, Böker K, Moog G, Baumgarten A, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Wedemeyer H, Manns MP, Schott E. Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS One 2015;10:e0134839. [PMID: 26230998 DOI: 10.1371/journal.pone.0134839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
547 Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51:845-852. [PMID: 19729219 DOI: 10.1016/j.jhep.2009.06.027.] [Reference Citation Analysis]
548 Cross TJ, Antoniades CG, Muiesan P, Al-Chalabi T, Aluvihare V, Agarwal K, Portmann BC, Rela M, Heaton ND, O’Grady JG. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382-1388. [PMID: 17902123 DOI: 10.1002/lt.21181] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
549 Blackadar CB. Systematic review of hepatocellular carcinoma mortality rates among hepatitis B virus-infected renal transplant recipients, with supplemental analyses of liver failure and all-cause mortality. Int J Infect Dis. 2013;17:e24-e36. [PMID: 23036372 DOI: 10.1016/j.ijid.2012.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
550 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 88] [Article Influence: 29.0] [Reference Citation Analysis]
551 Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2017;6:350-362. [PMID: 27739230 DOI: 10.1002/cpdd.318] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
552 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
553 Kubo S, Takemura S, Tanaka S, Shinkawa H, Nishioka T, Nozawa A, Kinoshita M, Hamano G, Ito T, Urata Y. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015;21:8249-55. [PMID: 26217076 DOI: 10.3748/wjg.v21.i27.8249] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
554 Lim SG, Mohammed R, Yuen M, Kao J. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of Gastroenterology and Hepatology 2009;24:1352-7. [DOI: 10.1111/j.1440-1746.2009.05985.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
555 Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Hirano K, Shimada Y, Iijima K, Wada R, Nagahara A, Watanabe S. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci. 2016;17. [PMID: 27999409 DOI: 10.3390/ijms17122143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
556 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
557 Borentain P, Garcia S, Gregoire E, Vidal V, Ananian P, Ressiot E, Hardwigsen J, Bartoli J, Moulin G, Botta-fridlund D, Le Treut YP, Gerolami R. Transjugular intrahepatic porto-systemic shunt is a risk factor for liver dysplasia but not hepatocellular carcinoma: A retrospective study of explanted livers. Digestive and Liver Disease 2015;47:57-61. [DOI: 10.1016/j.dld.2014.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
558 Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol. 2010;2:91-93. [PMID: 21160979 DOI: 10.4254/wjh.v2.i3.91] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
559 Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011;11:52. [PMID: 21261993 DOI: 10.1186/1471-2458-11-52] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
560 Ribes J, Clèries R, Rubió A, Hernández JM, Mazzara R, Madoz P, Casanovas T, Casanova A, Gallen M, Rodríguez C, Moreno V, Bosch FX. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006;119:687-94. [DOI: 10.1002/ijc.21882] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
561 Kim KA, Kim M, Choi J, Park M, Lim JS, Chung YE, Kim KW. Detection of recurrent hepatocellular carcinoma on post-operative surveillance: comparison of MDCT and gadoxetic acid-enhanced MRI. Abdom Imaging 2014;39:291-9. [DOI: 10.1007/s00261-013-0064-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
562 Wong YJ, Qiu TY, Ng GK, Zheng Q, Teo EK. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:615-23. [PMID: 33606427 DOI: 10.1097/MCG.0000000000001478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
563 Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012;32:837-844. [PMID: 22221966 DOI: 10.1111/j.1478-3231.2011.02734.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
564 Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; CHeCS Investigators. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93. [PMID: 24107395 DOI: 10.1016/j.cgh.2013.09.062] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 11.3] [Reference Citation Analysis]
565 Lee M, Yang H, Chen C. Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study. BioMedicine 2012;2:99-107. [DOI: 10.1016/j.biomed.2012.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
566 Liu N, Feng J, Lv Y, Liu Q, Deng J, Xia Y, Guo C, Zhou Y. Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study. Exp Ther Med 2019;18:4058-66. [PMID: 31611941 DOI: 10.3892/etm.2019.8011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
567 Park SH, Shim YS, Kim B, Kim SY, Kim YS, Huh J, Park JH, Kim KW, Lee SS. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. Eur Radiol 2021;31:4751-63. [PMID: 33389037 DOI: 10.1007/s00330-020-07577-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Abdelgawad IA. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients. J Clin Pathol 2015;68:154-60. [PMID: 25430496 DOI: 10.1136/jclinpath-2014-202462] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
569 Zhu J, Zhou Y, Wang L, Hao J, Chen R, Liu L, Li J. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1364-80. [PMID: 33457007 DOI: 10.21037/jgo-20-556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
570 Kresina TF, Sylvestre D, Seeff L, Litwin AH, Hoffman K, Lubran R, Clark HW. Hepatitis infection in the treatment of opioid dependence and abuse. Subst Abuse 2008;1:15-61. [PMID: 25977607 DOI: 10.4137/sart.s580] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
571 Bigsby RM, Caperell-Grant A. The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. Carcinogenesis 2011;32:1162-6. [PMID: 21606321 DOI: 10.1093/carcin/bgr094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
572 Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603-3615. [PMID: 20677332 DOI: 10.3748/wjg.v16.i29.3603] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 89] [Article Influence: 9.5] [Reference Citation Analysis]
573 Tseng T, Liu C, Yang H, Chen C, Yang W, Tsai C, Kuo SF, Verbree FC, Su T, Wang C, Liu C, Chen P, Chen D, Kao J. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64:292-302. [DOI: 10.1136/gutjnl-2014-306977] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
574 Racanelli V, Brunetti C, De Re V, Caggiari L, De Zorzi M, Leone P, Perosa F, Vacca A, Dammacco F. Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One 2011;6:e25606. [PMID: 21980500 DOI: 10.1371/journal.pone.0025606] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
575 Jiang J, Yan L, Shi Z, Wang L, Shan L, Efferth T. Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of Citrus changshan-huyou) on non-alcoholic fatty liver disease in rats via modulation of NF-κB and MAPKs. Phytomedicine 2019;64:153082. [DOI: 10.1016/j.phymed.2019.153082] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
576 Beal EW, Tumin D, Kabir A, Moris D, Zhang X, Chakedis J, Washburn K, Black S, Schmidt CM, Pawlik TM. Trends in the Mortality of Hepatocellular Carcinoma in the United States. J Gastrointest Surg 2017;21:2033-8. [DOI: 10.1007/s11605-017-3526-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
577 Zheng R, Wang L, Wang C, Yu X, Chen W, Li Y, Li W, Yan F, Wang H, Li R. Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning. Phys Med Biol 2021;66. [PMID: 33780910 DOI: 10.1088/1361-6560/abf2f8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
578 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 921] [Article Influence: 563.0] [Reference Citation Analysis]
579 Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Front Cardiovasc Med 2020;7:34. [PMID: 32211422 DOI: 10.3389/fcvm.2020.00034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
580 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
581 Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018;50:944-953. [PMID: 29735294 DOI: 10.1016/j.dld.2018.03.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
582 Güthle M, Dollinger MM. [Epidemiology and risk factors of hepatocellular carcinoma]. Radiologe 2014;54:654-9. [PMID: 24973122 DOI: 10.1007/s00117-014-2650-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
583 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013;5:311-322. [PMID: 23805355 DOI: 10.4254/wjh.v.5.i6.311] [Reference Citation Analysis]
584 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 202] [Article Influence: 78.3] [Reference Citation Analysis]
585 Jamwal R, Krishnan V, Kushwaha DS, Khurana R. Hepatocellular carcinoma in non-cirrhotic versus cirrhotic liver: a clinico-radiological comparative analysis. Abdom Radiol 2020;45:2378-87. [DOI: 10.1007/s00261-020-02561-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
586 Josephus Jitta D, Wagenaar LJ, Mulder BJ, Guichelaar M, Bouman D, van Melle JP. Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. International Journal of Cardiology 2016;206:21-6. [DOI: 10.1016/j.ijcard.2015.12.033] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
587 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
588 Gao J, Wang Z, Wang G, Gao N, Li J, Zhang Y, Zhou J, Zhang H, Wen Q, Jin H, Qiao H. From hepatofibrosis to hepatocarcinogenesis: Higher cytochrome P450 2E1 activity is a potential risk factor. Molecular Carcinogenesis 2018;57:1371-82. [DOI: 10.1002/mc.22851] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
589 Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J, Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer. 2011;129:2651-2661. [PMID: 21213212 DOI: 10.1002/ijc.25920] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
590 Wang Q, Zheng B, Ma B, Yang K; Cochrane Hepato-Biliary Group. Anterior approach versus conventional liver resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010545] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
591 Sureka B, Bansal K, Patidar Y, Kumar S, Arora A. Thoracic perspective revisited in chronic liver disease. Gastroenterol Rep (Oxf) 2015;3:194-200. [PMID: 25969457 DOI: 10.1093/gastro/gov017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
592 Fouquet A, Jambon AC, Canva V, Bocket-Mouton L, Gottrand F, Subtil D. [Hepatitis B and pregnancy. Part 1. Thirteen practical issues in antenatal period]. J Gynecol Obstet Biol Reprod (Paris) 2016;45:531-9. [PMID: 26964700 DOI: 10.1016/j.jgyn.2016.02.004] [Reference Citation Analysis]
593 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12] [Reference Citation Analysis]
594 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
595 Zhang Q, Qiao L, Liao J, Liu Q, Liu P, Liu L. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. J Cell Mol Med 2021;25:3772-84. [PMID: 33616276 DOI: 10.1111/jcmm.16249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
596 Jia QA, Wang ZM, Ren ZG, Bu Y, Xie XY, Wang YH, Zhang L, Zhang QB, Xue TC, Deng LF. Herbal compound “Songyou Yin” attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med. 2013;13:89. [PMID: 23622143 DOI: 10.1186/1472-6882-13-89] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
597 Liang T, Mok K, Liu S, Huang S, Chou N, Tsai C, Chen I, Yeh M, Chen Y, Wang B. Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma. Journal of the American College of Surgeons 2010;211:580-6. [DOI: 10.1016/j.jamcollsurg.2010.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
598 Yan PG, Wang RY, Zhang J, Cong WM, Dong H, Yu HY, Lau WY, Wu MC, Zhou WP. Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study. J Gastrointest Surg 2018;22:872-83. [PMID: 29313290 DOI: 10.1007/s11605-017-3638-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
599 Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, Yao B, Wang Y, Yang W, Liu Q, Tu K, Liu Z. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics 2020;10:5790-801. [PMID: 32483419 DOI: 10.7150/thno.44789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
600 Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012;56:855-861. [PMID: 22178270 DOI: 10.1016/j.jhep.2011.11.017] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
601 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
602 Chappell G, Kutanzi K, Uehara T, Tryndyak V, Hong HH, Hoenerhoff M, Beland FA, Rusyn I, Pogribny IP. Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer 2014;134:2778-88. [PMID: 24242335 DOI: 10.1002/ijc.28610] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
603 Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value in Health 2008;11:527-38. [DOI: 10.1111/j.1524-4733.2007.00297.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 82] [Article Influence: 7.6] [Reference Citation Analysis]
604 Hayes CN, Chayama K. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2016;17:280. [PMID: 26927063 DOI: 10.3390/ijms17030280] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 22.4] [Reference Citation Analysis]
605 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
606 Baligar P, Mukherjee S, Kochat V, Rastogi A, Mukhopadhyay A. Molecular and Cellular Functions Distinguish Superior Therapeutic Efficiency of Bone Marrow CD45 Cells Over Mesenchymal Stem Cells in Liver Cirrhosis. Stem Cells. 2015; Sep 21. [Epub ahead of print]. [PMID: 26389810 DOI: 10.1002/stem.2210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
607 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
608 Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg 2015;209:199-205. [PMID: 25312843 DOI: 10.1016/j.amjsurg.2014.03.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
609 Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig Dis Sci. 2012;57:3265-3270. [PMID: 22695885 DOI: 10.1007/s10620-012-2260-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
610 Zheng K, Cubero FJ, Nevzorova YA. c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) 2017;8:E123. [PMID: 28422055 DOI: 10.3390/genes8040123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
611 Liu Z, Ling Q, Wang J, Xie H, Xu X, Zheng S. Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett 2013;6:125-9. [PMID: 23946789 DOI: 10.3892/ol.2013.1337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
612 Li Q, Wang L, Tan W, Peng Z, Luo Y, Zhang Y, Zhang G, Na D, Jin P, Shi T, Ma D, Wang L. Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-κB pathways and promotes cell survival in human cancer cells. Cancer Lett 2011;308:203-14. [PMID: 21658842 DOI: 10.1016/j.canlet.2011.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
613 Rahimi R, Yopp A, Singal A. Current issues and future trends in surveillance for hepatocellular carcinoma. Clin Liver Disease. 2012;1:186-189. [PMID: 31186884 DOI: 10.1002/cld.115] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
614 Wang ZY, Tao QF, Wang ZH, Lin KY, Huang G, Yang Y, Zhou WP, Lau WY. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study. Am J Surg 2020;219:717-25. [PMID: 31266631 DOI: 10.1016/j.amjsurg.2019.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
615 Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. Hepatol Res 2015;45:415-22. [PMID: 24861870 DOI: 10.1111/hepr.12365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
616 Hou X, Ye F, Li X, Liu W, Jing Y, Han Z, Wei L. Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis. Cellular Immunology 2018;326:52-9. [DOI: 10.1016/j.cellimm.2017.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
617 Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6. [PMID: 27438343 DOI: 10.1080/00365513.2016.1210328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
618 Nahon P, Kettaneh A, Lemoine M, Seror O, Barget N, Trinchet JC, Beaugrand M, Ganne-Carrié N. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. Eur J Gastroenterol Hepatol. 2009;21:214-219. [PMID: 19212210 DOI: 10.1097/meg.0b013e32830eb8d7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
619 Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009;15:5080-5. [PMID: 19860002 DOI: 10.3748/wjg.15.5080] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
620 Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, de Julian Fernandez C, Cappello V, Gemmi M, Moscato S, Ronca F, Sacco R, Mattoli V, Ciofani G. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Adv Healthcare Mater 2015;4:1681-90. [DOI: 10.1002/adhm.201500235] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
621 Mazzocca A, Birgani MT, Sabbà C, Carloni V. Tetraspanin-enriched microdomains and hepatocellular carcinoma progression. Cancer Lett 2014;351:23-9. [PMID: 24858024 DOI: 10.1016/j.canlet.2014.05.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
622 Lapalus M, Laouenan C, Cardoso AC, Estrabaud E, Carvalho-Filho RJ, Zhang Q, Lada O, Appourchaux K, Mouri F, Boyer N, Bedossa P, Asselah T, Martinot-Peignoux M, Marcellin P. Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B. Liver Int. 2015;35:2082-2089. [PMID: 25612083 DOI: 10.1111/liv.12787] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
623 Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int 2019;39:1098-108. [PMID: 30829446 DOI: 10.1111/liv.14087] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
624 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
625 Sato S, Genda T, Ichida T, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Mori M. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1315-1322. [PMID: 26758591 DOI: 10.1111/jgh.13295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
626 Dai CY. Treatment uptake of patients with chronic hepatitis C: can we expect and do more? Dig Dis Sci 2010;55:3300-3. [PMID: 20976622 DOI: 10.1007/s10620-010-1452-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
627 Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract. 2010;2010:710381. [PMID: 20827314 DOI: 10.1155/2010/710381] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
628 Zeuzem S. [Chronic hepatitis C : Standard treatment and remaining challenges]. Internist (Berl) 2018;59:528-35. [PMID: 29696303 DOI: 10.1007/s00108-018-0429-y] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
629 Sasidharan SP, Vasumathi AV. In vitro pharmacological, in vivo toxicological and in silico molecular docking analysis of glycopentalone, a novel compound from Glycosmis pentaphylla (Retz.) Correa. Med Chem Res 2017;26:1697-707. [DOI: 10.1007/s00044-017-1880-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
630 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
631 Liu Y, He J, Li C, Benitez R, Fu S, Marrero J, Lubman DM. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res. 2010;9:798-805. [PMID: 19961239 DOI: 10.1021/pr900715p] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
632 Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016;65:663-665. [PMID: 27417216 DOI: 10.1016/j.jhep.2016.07.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
633 Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, Huang J, Mao Y. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014;29:597-602. [PMID: 24236824 DOI: 10.1111/jgh.12461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
634 Howard BA, Wong TZ. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am 2021;59:737-53. [PMID: 34392916 DOI: 10.1016/j.rcl.2021.06.001] [Reference Citation Analysis]
635 Péneau C, Zucman-Rossi J, Nault JC. Genomics of Viral Hepatitis-Associated Liver Tumors. J Clin Med 2021;10:1827. [PMID: 33922394 DOI: 10.3390/jcm10091827] [Reference Citation Analysis]
636 Conti F, Vitale G, Andreone P. Treating hepatitis C in the elderly: the future is near? Expert Opin Pharmacother 2014;15:2019-28. [PMID: 25154694 DOI: 10.1517/14656566.2014.945422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
637 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol. 2013;5:364-371. [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
638 Mehinovic L, Islamagic E, Husic-Selimovic A, Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. Open Access Maced J Med Sci 2018;6:1668-73. [PMID: 30337985 DOI: 10.3889/oamjms.2018.344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
639 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 2019;25:1550-1559. [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 30] [Article Influence: 19.0] [Reference Citation Analysis]
640 Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol 2020;20:84. [PMID: 32245414 DOI: 10.1186/s12876-020-01239-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
641 Beal EW, Albert S, McNally M, Shirley LA, Hanje J, Michaels AJ, Black SM, Bloomston M, Schmidt CR. An indeterminate nodule in the cirrhotic liver discovered by surveillance imaging is a prelude to malignancy. J Surg Oncol 2014;110:967-9. [PMID: 25155168 DOI: 10.1002/jso.23765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
642 Sersté T, Barrau V, Ozenne V, Vullierme M, Bedossa P, Farges O, Valla D, Vilgrain V, Paradis V, Degos F. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology 2012;55:800-6. [DOI: 10.1002/hep.24746] [Cited by in Crossref: 108] [Cited by in F6Publishing: 85] [Article Influence: 12.0] [Reference Citation Analysis]
643 Sposito C, Di Sandro S, Brunero F, Buscemi V, Battiston C, Lauterio A, Bongini M, De Carlis L, Mazzaferro V. Development of a prognostic scoring system for resectable hepatocellular carcinoma. World J Gastroenterol 2016;22:8194-202. [PMID: 27688661 DOI: 10.3748/wjg.v22.i36.8194] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
644 Liu J, Wu Z, Zhang J, Xie Y, Sun P, Wu H, Chang X, Zhang L, Liu F. Effect of partial splenic embolization on transarterial chemoembolization for hepatocellular carcinoma with hypersplenism. Medicine 2021;100:e26441. [DOI: 10.1097/md.0000000000026441] [Reference Citation Analysis]
645 Jariwala N, Sarkar D. Emerging role of lncRNA in cancer: a potential avenue in molecular medicine. Ann Transl Med 2016;4:286. [PMID: 27569205 DOI: 10.21037/atm.2016.06.27] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
646 Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis. Ann Surg Oncol 2014;21:458-65. [PMID: 24132624 DOI: 10.1245/s10434-013-3302-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
647 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 21.0] [Reference Citation Analysis]
648 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
649 Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019;7:pii: E121. [PMID: 31060311 DOI: 10.3390/microorganisms7050121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
650 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
651 Reddy A, May E, Ehrinpreis M, Mutchnick M. Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C. World J Gastroenterol. 2013;19:9328-9333. [PMID: 24409059 DOI: 10.3748/wjg.v19.i48.9328] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
652 Zhu S, Li Y, Zhang Y, Wang X, Gong L, Han X, Yao L, Lan M, Zhang W. Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma. Hepatol Res 2015;45:97-106. [PMID: 24593119 DOI: 10.1111/hepr.12320] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
653 Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-1154. [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019] [Cited by in Crossref: 148] [Cited by in F6Publishing: 146] [Article Influence: 12.3] [Reference Citation Analysis]
654 Hu J, Ludgate L. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat Res. 2007;133:241-252. [PMID: 17672044 DOI: 10.1007/978-0-387-46816-7_9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
655 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44 Suppl 19:96-101. [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6] [Cited by in Crossref: 135] [Cited by in F6Publishing: 129] [Article Influence: 11.3] [Reference Citation Analysis]
656 Su H, Zhang Y, Xu D, Wang B, Zhang L, Li D, Xiao D, Li F, Zhang J, Yan Y. Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS One. 2013;8:e70768. [PMID: 23951004 DOI: 10.1371/journal.pone.0070768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
657 Gao X, Qiao X, Xing X, Huang J, Qian J, Wang Y, Zhang Y, Zhang X, Li M, Cui J, Yang Y. Matrix Stiffness-Upregulated MicroRNA-17-5p Attenuates the Intervention Effects of Metformin on HCC Invasion and Metastasis by Targeting the PTEN/PI3K/Akt Pathway. Front Oncol 2020;10:1563. [PMID: 32974191 DOI: 10.3389/fonc.2020.01563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
658 Liang KH, Cheng ML, Lo CJ, Lin YH, Lai MW, Lin WR, Yeh CT. Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: an exploratory study. Sci Rep 2020;10:10926. [PMID: 32616821 DOI: 10.1038/s41598-020-67971-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
659 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
660 Freitas N, Salisse J, Cunha C, Toshkov I, Menne S, Gudima SO. Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology. 2012;56:76-85. [PMID: 22334419 DOI: 10.1002/hep.25663] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
661 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 259] [Article Influence: 44.8] [Reference Citation Analysis]
662 Ferrara-Romeo I, Martínez P, Blasco MA. Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice. PLoS One 2018;13:e0204909. [PMID: 30307978 DOI: 10.1371/journal.pone.0204909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
663 Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol. 2014;6:504-512. [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
664 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 105] [Article Influence: 17.7] [Reference Citation Analysis]
665 Li J, Han X, Yu X, Xu Z, Yang G, Liu B, Xiu P. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res. 2018;37:213. [PMID: 30176913 DOI: 10.1186/s13046-018-0893-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 14.3] [Reference Citation Analysis]
666 Nowak AJ, Relja B. The Impact of Acute or Chronic Alcohol Intake on the NF-κB Signaling Pathway in Alcohol-Related Liver Disease. Int J Mol Sci 2020;21:E9407. [PMID: 33321885 DOI: 10.3390/ijms21249407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
667 Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. J Viral Hepat. 2011;18:e232-e241. [PMID: 21692938 DOI: 10.1111/j.1365-2893.2011.01440.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
668 Trevisani F, Magini G, Santi V, Morselli-labate AM, Chiara Cantarini M, Anna Di Nolfo M, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; for the Italian Liver Cancer (ITA.LI.CA) Group. Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. CME. Am J Gastroenterology 2007;102:1022-31. [DOI: 10.1111/j.1572-0241.2007.01100.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
669 Lin Y, Lin G, Fang W, Zhu H, Chu K. Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype. Med Oncol 2014;31:327. [PMID: 25412936 DOI: 10.1007/s12032-014-0327-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
670 Daniele B, Perrone F. Staging for Liver Cancer. Clinics in Liver Disease 2005;9:213-23. [DOI: 10.1016/j.cld.2004.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
671 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
672 Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 2015;21:12150-6. [PMID: 26576099 DOI: 10.3748/wjg.v21.i42.12150] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
673 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [C